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PREVENTION 
 
 
ABSTRACT 
 
  Non-communicable diseases (cardiovascular diseases, cancers, chronic respiratory 
diseases, diabetes, and mental illnesses) and associated risk factors (unhealthy diets, physical 
inactivity, harmful use of alcohol, physical inactivity) are on the rise in developing countries, 
posing a threat to the health and financial systems of emerging economies. 
  In response, international organizations and Ministries of Health alike have started to 
tackle chronic diseases and associated risk factors with policies and treatment programs. Yet to 
this day, the body of evidence for best practices regarding the monitoring, prevention, and 
control of non-communicable diseases in low- and middle-income countries remains small. 
  This doctoral thesis adds to this body of evidence. The first paper of my thesis assesses 
the impact of a national tobacco control program in high schools in Chile. Specifically, it 
evaluates the effectiveness and makes several policy recommendations based on the findings. 
My second dissertation paper assesses the modifying effect of a change in anti-retroviral 
treatment among HIV-positive subjects in KwaZulu-Natal, South Africa on cardiovascular 
disease risk factors of high body mass index and high blood pressure. The third paper is based on 
	   iii	  
a randomized controlled trial assessing the effectiveness of a social-network-based diabetes and 
weight management program in Jordan. 
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INTRODUCTION 
 
 
Non-communicable diseases (cardiovascular diseases, cancers, chronic respiratory diseases 
(COPD), diabetes, and mental illnesses) and associated risk factors (unhealthy diets, tobacco use, 
harmful use of alcohol, physical inactivity) are on the rise in developing countries. Globally, 
Ischemic heart disease, stroke, and COPD are the three leading causes of mortality1, and non-
communicable diseases (NCDs) constitute close to 54% of the overall disease burden, as 
measured in disability adjusted life years (DALYs).2 NCD risk factors of high blood pressure 
and tobacco smoking topped the global burden of disease charts in 2010, usurping childhood 
underweight as the number one contributor to global DALYs in 1990.3 NCDs are also major 
drivers of costs to national healthcare systems. A recent report on the Global Economic Burden 
of NCDs in low and middle income countries estimated that under ‘business as usual’ conditions, 
cumulative losses from cancer, diabetes, cardiovascular diseases, and COPD will surpass US$47 
trillion between 2011 and 2025.4  
In light of the increasing disease and financial burden of NCDs in low and middle income 
countries, international organizations and Ministries of Health alike have started to tackle 
chronic diseases and associated risk factors with policies and treatment programs.5 However, the 
body of evidence for best practices regarding the monitoring, prevention, and control of NCDs in 
LMICs is small. The following three areas are in particular need of further studies: 1) Monitoring 
and assessment of national policies directed at curbing NCDs, particularly those focused on 
tobacco control6; 2) Monitoring and management of chronic-infectious disease co-morbidities in 
LMICs - it remains unclear how NCD prevention and treatment efforts interact with the rise in 
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comorbidities, especially in settings with high prevalence of HIV and TB7,8; 3) Evidence on 
effective NCD risk factor prevention programs in emerging economies.4 
My doctoral thesis adds to this body of evidence. The first paper of my thesis assesses the impact 
of a national tobacco control program in high schools in Chile. Specifically, it evaluates the 
effectiveness and makes several policy recommendations based on the findings. It was accepted 
for publication by the Bulletin of the WHO. My second dissertation paper assesses the modifying 
effect of a change in ART treatment among HIV-positive subjects in KwaZulu-Natal, South 
Africa on cardiovascular disease risk factors of body mass index (BMI) and high blood pressure 
(Abstract published by Lancet Global Health). The third paper is based on a randomized 
controlled trial assessing the effectiveness of a social-network-based diabetes and weight 
management program in Jordan (Invited for submission by Annals of Internal Medicine). 
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ABSTRACT 
 
 
Objective. In 2005, Chile passed an anti-smoking legislation that included a complete smoking 
ban in all high schools and a tobacco sales ban within 300 meters of all schools. This study 
evaluates the bans’ impact on smoking behavior among high school students. 
 
Methods. We conducted an interrupted time series analysis, using repeated cross-sectional data 
from Chile’s School Population Survey SENDA-SPS (2000-2011) for high school students (ages 
12-18) and a university-age control group (ages 19-24). Poisson regression models were used to 
assess trends in smoking behavior before and after the policy change. The two outcome measures 
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were self-reported past 30-day smoking prevalence (binary), and prevalence of frequent smoking 
(smoking 15 or more days per month, yes/no). 
 
Findings. From 2005 to 2011, smoking prevalence declined among high-school students by 
6.8% per year, which was 2.9% (95% CI: 0.18, 5.00, p=0.009) greater than the analogous decline 
among the university students. We estimated that after 5-6 years of enforcing the law, smoking 
prevalence among high school students was 13.7% lower than the level it would have been 
without the ban. The impact of the smoking ban was primarily driven by declines in smoking 
prevalence among students in grades 8 to10.  The smoking ban had no significant impact on 
frequent smoking. 
 
Conclusion. The 2005 school smoking ban was successful in reducing smoking prevalence 
among younger high school students in Chile, but future interventions targeting older individuals 
and more frequent smokers may be needed. 
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INTRODUCTION 
 
The detrimental health effects of smoking and tobacco use are widely documented.1-7 Every year, 
five million deaths occur globally due to first-hand smoking.8 Eight out of ten smoking-related 
deaths occur in low- and middle-income countries.8,9	   Despite the strong evidence that links 
smoking to increased mortality and morbidity and the potential effectiveness of strictly enforced 
policies such as public smoking bans10, subsidized cessation programs11-13, tobacco warning 
labels14-16, and tax increases17-20, countries with emerging economies and thus increased 
disposable incomes often play legislative catch-up to counter increased smoking trends, and the 
impacts of these legislative changes differ based on context.  
 
One country that has experienced consistent economic growth, but is still battling high smoking 
rates, is Chile. As of 2011, Chile remained the country with the highest smoking rates in Latin 
America21,22 and with the second highest teenage smoking rate globally.9 To counter these 
trends, on June 13th, 2005, Chile ratified the Framework Convention on Tobacco Control 
(FCTC).23 This provided momentum for the new tobacco Law #20.10524, which took effect on 
January 1st 2006. 
 
The strongest provision in the law is the high school smoking ban: it was the only provision of 
Law #20.105 that was enforced with 100% reported compliance, and that targeted a specific 
population subgroup (high school students) (See Supplementary Appendix 1.2 & 1.3). These two 
factors allow for an impact evaluation of the law by comparing its impact on teenagers versus 
young adults. Indeed, preliminary evidence suggests that smoking rates in high school students 
have declined from 2005 - 2011, but that smoking in the general adult population did not decline 
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significantly.22 To our knowledge, this trend, as well as the overall effectiveness of school 
smoking bans, have not yet been rigorously evaluated in the scientific literature.25 Hence, the 
goal of this paper is to evaluate the ban’s impact on smoking prevalence among high school 
students. 
 
METHODS 
 
Study Design 
The analysis followed an interrupted time series (ITS) design with a comparison group, 
quantifying the impact of the school smoking ban by evaluating trends in smoking prevalence 
before and after the ban in the target population (high school students 12-18 years), in 
comparison to trends over the same periods in a group presumed unaffected by the ban. We used 
the general population aged 19-24 years as the comparison population, given that over 40% of 
the 19-24 year old population attended university or a post-secondary institution in 2008 in 
Chile26 (and hence were in a similar institutional environment), that most Chileans who smoke 
started smoking in their last years of high school or first year after high school, and that the 
smoking ban was implemented in schools, but not in universities or workplaces. Notably, the 
comparison population in 2000/01 to 2006/07 included the surveyed general population age 19 – 
24 years; in 2008/09 it included all 20-24 year olds; in 2010/11 it included all 22 – 24 year olds. 
This was to ensure the control group did not include anyone subjected to the ban when still in 
high school. 
Data 
For the intervention population, we used data from School Population Survey (SENDA-SPS) – a 
biennial, and regionally representative survey on substance abuse and addictive behavior in the 
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Chilean school population, including the last grade of primary school (equivalent to 8th grade), 
and the high school population (equivalent of 9th – 12th grade). SENDA-SPS was conducted in 
the fall of every odd year, and data starting in 2001 were included in the analyses.27  
For the comparison population, we used data from the General Population Survey (SENDA-
GPS), conducted in even years, for 2000-2010.27  (See Supplementary Appendix 1 for more 
details on data structure).  
We combined SENDS-SAP and DENDA-GPS, resulting in a dataset containing three waves 
before the law (2000-01, 2002-03, 2004-05) and three waves after (2006-2007, 2008-09, 2010-
11), including different individuals each time, with an average sample size of ~50,000 
individuals per biennium in SENDA-SPS and ~ 2,300 individuals in SENDA-GPS per biennium 
(See Supplementary Appendix 1, Tables S1.3 – S1.5). The SENDA-SPS and SENDA-GPS 
datasets are publicly available. 
Statistical analysis 
Trends in smoking prevalence rates in the high school population before and after the policy 
change were compared to those in the comparison population. The main outcome measure was 
self-reported, past 30-day smoking prevalence (yes/no). As a secondary outcome, we created a 
‘frequent smoking’ variable that was a binary indicator for smoking 15 or more days per month 
during the last month (yes/no).  
In general, the estimation of prevalence rate ratios (rather than odds ratios) is of interest when 
common outcomes are involved.28 Thus, we used the robust Poisson model to model the binary 
outcomes of past 30-day smoking and frequent smoking, which allowed for robust and direct 
estimation of prevalence ratios.9,29-31 In the first stage, the robust Poisson models were run 
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separately for control and intervention groups due to different variances arising from different 
samples and sample frames. Robust standard errors were clustered at the municipality level. In 
the Poisson models, the primary independent variables were coefficients reflecting the annual 
rate of change in smoking prevalence during the post-intervention period, relative to the annual 
rate of change in the pre-intervention period. In multivariable regression, we controlled for age, 
sex, an interaction term for age and sex, school type, grade-level, region, and grade point average 
in the intervention group; and for age, sex, age*sex, socioeconomic status, method of survey 
administration, and region in the control group. Missingness in covariates was generally lower 
than 2% and the complete case method was chosen for the main analysis. The second stage was a 
two-sample t-test with unequal variances conducted on the estimated coefficient for post-
intervention change in the intervention group compared to the coefficient in the control group. 
All analyses were performed using STATA 12.  
We conducted numerous sensitivity analyses to evaluate the robustness of our base-case results 
on smoking prevalence.  These included: (1) including all 19-24 year olds in the control 
population; (2) running analogous analyses using past 30-day marijuana use as the main outcome 
(to test for the specificity of the school smoking ban on smoking behavior versus addictive 
behavior in general); (3) including only those municipalities measured in every survey year; (4) 
excluding individuals with less than high school education in the control group; (5-6) including 
past month alcohol prevalence, religion, and paternal education as additional control variables; 
(7) adjusting for survey weights; (8) adjusting for complex survey design; (9) using SENDA-
GPS 19-64 year olds as the control population; and (10) using the missing indicator method to 
account for missingness.32 For investigating the impact of the law on smoking frequency, we 
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conducted the following two sensitivity analyses: (1) adjusting for complex survey design; and 
(2) stratifying the analysis by grade level in the intervention group. 
 
RESULTS 
 
Descriptive statistics for the intervention and control samples are presented in Table 1.1. 
Unadjusted for covariates, 30-day smoking prevalence among high school students was highest 
in 2001, with a prevalence of 41.9%, slightly declining to 40.1% in 2004-05. After the law, the 
smoking prevalence in this population declined to 25.7% in 2010-11. Smoking prevalence 
among the university aged comparison population was overall higher. By 2008-09, the 
prevalence was 50.0%, and dropped to 44.9% by 2010. Immediately after 2005, there was a 
slightly steeper decline in smoking prevalence among high school students than among the 
university age population.  
Smoking frequency (days smoked during last 30 days) was overall higher in the university-aged 
population than in the high school population.  In 2002-03, high school smokers smoked an 
average of 16.5 days per month, which declined to 15.0 days/month in 2006/07, further dropping 
to 13.0 days per month in 2010-11. Number of days smoked per month in the comparison group 
was relatively flat over the examined time period, with a peak level of 21.4 days during 2004-05, 
and a level of 19.9 days smoked in 2010-11. Of note, smoking prevalence and frequency among 
smokers increased with increasing school grade. Smoking frequency was also highest in 12th 
graders versus 8th graders, and average smoking frequency was highest in 2002-03 and lowest in 
2010-11 in all groups and grades (Data shown in Supplementary Appendix 1, Tables S1.3 – 
S1.7). 
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Impact of law on smoking prevalence 
Adjusting for covariates in the multivariable regression model, smoking prevalence increased 
among high school students over the period 2000-2005, at an estimated annual rate of 0.6 % per 
year (p=0.014); the annual rate of change in the university-age control group over this same 
period was not significantly different from zero. Post 2006, there was an annual decline in 
smoking among the high school group of 6.8 % per year, which represents a 7.4 % improvement 
in the rate of change in smoking compared to the pre-intervention trend in the high school 
population alone. This improvement in the smoking trend in the high school group after the ban 
was 2.9 % greater (95% CI: 0.18, 5.00, p=0.009) than the analogous difference in the university-
age group. Accounting for the additional change in the intervention group compared to the 
control, we estimate that smoking prevalence among high school students in the year 2010 was 
13.7% lower than it would have been without the ban (Table 1.2). 
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Table 1.2: Main results from the 2-stage marginal fixed effects Poisson model testing the impact of the 2005 
law on smoking prevalence. The presented RRs represent the annual dose response decrease in smoking 
prevalence. The first stage model of the high school population was adjusted for age, sex, region, school-type, 
course, and sex*age. The first stage model of the university-aged population included age, sex, region, SES, survey 
method, and sex*age. (CI = Confidence Interval; RR = Relative Risk).  
Stage 1a: High School Students 
RR of 1-year 
prevalence change 
(95% CI) 
RR of 1-year 
Difference in 
Prevalence change 
RR of Difference in post-policy 
prevalence change 
Pre-Policy Annual Prevalence Rate 
change 
1.01 (1.00, 1.01) 
p=0.014 0.926 (0.917, 
0.934) p<0.001 Policy Intervention 1-year effect:  
0.971 (0.950, 0.992)  
p = 0.0085 
 
 
Policy Intervention 5-year effect:  
0.863 (0.774, 0.961)  
p = 0.0085 
 
Post-Policy Annual Prevalence Rate 
change 
 
0.932 (0.927, 
0.937) p<0.001 
Stage 1b: University-age Control 
Group   
Pre-Policy Annual Prevalence Rate 
change 
 
1.01 (0.999, 
1.02)  
1.02 p = 0.065 
 
0.953 (0.935, 
0.973) p<0.001 Post-Policy Annual Prevalence Rate 
change 
0.964 (0.953, 
0.974) p < 0.001 
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Since the descriptive analysis (Table S1.6, Supplementary Appendix 1) revealed a stark 
difference in smoking prevalence among different high school grades, a grade-based stratified 
analysis was performed to determine the grades in which the law had the greatest impact. The 
results of these analyses are shown in Table 1.3. The smoking ban had the greatest impact on 
those students who were lowest prevalence smokers: the smoking ban was most effective among 
8th graders (leading to a 7.2 % (95% CI: 10.1%, 4.3%, p<0.0001) annual improvement in 
smoking trend in the HS population versus the control population after the ban), and least 
effective among 11th and 12th graders, for which the smoking ban had no significant impact on 
smoking prevalence.  
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Table 1.3: Main results from the 2-stage marginal fixed effects Poisson model testing the impact of the 2005 
law on smoking prevalence for each high school grade. The presented RRs represent the annual dose response 
decrease in smoking prevalence. The first stage model of the high school population was adjusted for age, sex, 
region, school-type, course, and sex*age. The first stage model of the university-aged population included age, sex, 
region, SES, survey method, and sex*age. (CI = Confidence Interval; RR = Relative Risk). 
Population and Study 
Period 8
th grade 9th grade 10th grade 11th grade 12th grade 
 Stage 1a: HS Group (Targeted Intervention Population) 
Pre-Policy Annual 
Prevalence 
Rate change 
1.02 (1.001, 
1.03) p=0.037 
1.01 (0.999, 1.02) 
p=0.075 
1.01 (0.999, 
1.02) p=0.081 
0.998 (0.990, 1.01) 
p=0.641 
0.995 (0.941, 
1.00) p=0.263 
Post-Policy Annual 
Prevalence 
Rate change 
0.898 (0.886, 
0.910) p 
<0.001 
0.930 (0.923, 
0.938) p<0.001 
0.930 (0.923, 
0.937) p<0.001 
0.940 (0.934, 
0.947) p<0.001 
0.948 (0.941, 
0.956) p<0.001 
Difference in 
Prevalence change 
0.885 (0.864, 
0.906) p<0.001 
0.922 (0.908, 
0.937) p<0.001 
0.923 (0.911, 
0.936) p<0.001 
0.942 (0.930, 
0.955) p<0.001 
0.953 (0.940, 
0.967) p<0.001 
 Stage 1b: University-aged Group (Comparison Population) 
Pre-Policy Annual 
Prevalence Rate 
change 
1.01 (0.999, 1.022) p = 0.065 
Post-Policy Annual 
Prevalence Rate 
change 
0.959 (0.926, 0.993) p=0.02 
Difference in 
Prevalence change 0.931 (0.927, 0.935) p<0.001 
 Stage 2: Two sample mean-comparison test 
Intervention Effect 
0.928 
(0.899, 0.957) 
p<0.0001 
0.967 
(0.943, 0.992) 
p=0.01 
0.968 
(0.945, 0.992) 
p=0.0089 
0.988 
(0.965, 1.01) 
p=0.3276 
1.00 
(0.975, 1.02) 
p=0.9797 
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Table 1.4: Results from the 2-stage marginal fixed effects Poisson model testing the impact of the 2005 
law on heavy smoking. The presented RRs represent the annual dose response in smoking frequency. The first 
stage model of the high school population was adjusted for age, sex, region, school-type, course residual, and 
sex*age. The first stage model of the university-aged population included age, sex, region, SES residual, 
survey method, and an interaction between sex and age. (CI = Confidence Interval; RR = Relative Risk). 
Stage 1a: High School Group RR of prevalence change (95% CI) 
RR of Difference 
in Prevalence 
change 
RR of Difference in post-
policy prevalence change 
Pre-Policy Annual change in frequency 
 
0.975 (0.959, 
0.992) p=0.004  
0.947 (0.926, 
0.969) p<0.001 
Policy Intervention effect:  
0.986 (0.938, 1.036) p=0.580 
Post-Policy Annual change in frequency 
 
0.924 (0.916, 
0.932) p<0.001 
Stage 1b: University-aged Group   
Pre-Policy Annual change in frequency 
 
0.992 (0.959, 1.03) 
p=0.669 
0.961 (0.919, 1.00) 
p=0.079 
Post-Policy Annual change in frequency 0.953 (0.938, 0.969 p<0.001 
     
 
 
Impact of Law on Frequent Smoking 
Prior to the change in law, in years 2000-2005, prevalence of frequent smoking (defined as 
smoking at least 15 of the past 30 days) in the intervention group declined by 2.5% annually 
2000-2005 (95% CI: -4.1%, -0.8%, p=0.004); frequent smoking prevalence in the comparison 
group showed no significant trend in this period. Post – 2005, the difference in the frequent 
smoking prevalence change between the intervention and comparison group was not significant 
(p=0.58).  
Sensitivity analyses  
Detailed results from sensitivity analyses are presented in the Supplementary Appendix 1, and 
key findings summarized here. When examining the pre- and post-law prevalence changes in 
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marijuana use, past 30-day marijuana use after 2005 increased by 14% (95% CI: 11%, 18%; 
p<0.0001) annually in the high school population versus the control population.   
Further sensitivity analyses including only those municipalities included in all years yielded 
identical effect size estimates as the main analysis (Table S1.8). When including only those with 
a high school diploma in the control population, the effect size for the smoking ban increased to 
4.5 % (CI: 1.3, 7.5; p=0.0056). Adjusting for past-month alcohol prevalence, religion, and 
paternal education (in the high school population) led to an almost doubling in effect size 
estimate (to 4.8% (CI: 2.4, 6.4; p<0.0001)).  
With regard to the sensitivity analyses for the impact of the law on frequent smoking, sampling-
weight and complex survey adjusted models (results not shown) also revealed no significant 
difference in heavy smoking prevalence change before and after the law in control versus 
comparison groups. This result remained robust when stratifying by grade levels, also (Table 
S1.11). 
 
DISCUSSION  
 
Using repeated cross-sectional data for 319,798 Chileans observed between the years 2000 and 
2011, employing a strong quasi-experimental design, we find that the change in trends for past-
30-day smoking prevalence before and after the 2005 smoking ban was significantly greater in 
high school students than in the university-age control group. Smoking prevalence declined by 
an additional 2.9% annually among high school students after the implementation of the plan, 
compared to the post-intervention trend observed in the control group; this is a considerable 
	   19 
decline given that the teenage smoking rate in Chile remains the highest in Latin America and 
among the highest in the world.1 
 
The average intervention effect was driven by the decline in smoking prevalence among younger 
high school students. In contrast, the smoking ban proved ineffective in lowering smoking 
prevalence among older high school students, as well as in lowering the prevalence of frequent 
smoking (i.e. 15 or more days per month). In combination, these results suggest that the smoking 
ban prevented smoking initiation and selectively targeted low frequency smokers. These findings 
are consistent with Becker and Murphy’s theory33 that those with least myopic preferences (non-
smokers or less frequent smokers) are most positively impacted by anti-tobacco policies. The 
results have policy salience and practical implications, highlighting that 100% smoke free zones 
including tobacco sales restrictions can be highly effective in the Chilean context. Nonetheless, 
our findings that the law did not impact frequent smokers stress the need for better-targeted 
programs and policies. Examples of proven-effective programs that focus on high frequency 
smokers include smoking cessation counseling programs (in high schools) and free prescription 
nicotine patches11. Legislation featuring such programs has been proposed, but not yet passed or 
funded in Chile, in large parts due to lobbying efforts by the tobacco industry.  
 
Several sensitivity analyses confirmed the robustness of our results: When including all 19-24 
year olds in all years in the control population, we found that the effect size estimate was lower. 
This was expected, since the control population in 2008 and 2010 also included people 
previously exposed to the law. In contrast, when including only those with a high school diploma 
in the control population, the effect size increased. A possible explanation is that those with at 
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least a high school diploma continued (rather than altered) their smoking behavior between ages 
19-24 years. The sensitivity analysis with marijuana use as the main outcome revealed that 
relative to the control population, marijuana use in high school students increased by 14% in the 
examined period after the law. This is further evidence that the decline in teenage smoking rates 
is directly attributable to the high school smoking ban. Our findings confirm the conclusions by 
Horner et al. that the difficulty of obtaining cigarettes was associated with lower smoking 
prevalence among Chilean teenagers.34 Thus, recreational drug use might increase after the 
introduction of stricter tobacco laws, and needs to be monitored closely and pre-empted in 
similar settings. 
 
In addition to the immediate effect, another important consideration is the law’s long-term 
impact on the disease burden. There is emerging evidence that adolescence is a most critical 
window to form (or prevent the forming of) long-term addictive behaviors.35-37 A recent survey 
on societal factors associated with smoking in Chilean teenagers concluded that increased 
difficulty in obtaining cigarettes was associated with less positive views about smoking in 
adolescents.38 Grucza et al. concluded that while there might be long-term effects of youth access 
laws, these might be limited to women only.39 Messer et al. showed that smoking cessation rates 
in the US population were highest in the age group <35 years, which the authors hypothesized to 
be closely related to changing norms about smoking in the workplace.40 Thus, emerging 
evidence points towards the plausibility that adolescent smoking bans can have long-lasting 
impacts.  
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How large could the long-term disease impact of the Chilean high school smoking ban be? For 
example, a life table approach to assess long-term impact on morbidity has been used to show 
that in male age groups as young as 35-39 years of a 1960-1972 American cohort, the death rate 
in those who never smoked regularly was 1.34, versus 2.55 in those who smoked one or more 
packs of cigarettes per day.41 At age 40-44, the death rates in male never-smokers were 1.93, 
versus 4.59 in heavy smokers. Overall death rates in females were lower in both smokers and 
nonsmokers, but still substantially higher in heavy smokers versus non-smokers. Assuming that 
the mortalities from a 1960-1972 American cohort apply to the current Chilean high school 
cohort, and that the prevalence impact persists over the next 15 -20 years, the Chilean high 
school smoking ban potentially could affect a >2 fold reduction in mortality in those prevented 
from smoking by the ban as early as 20 years from now. This would be considerable both based 
on a public health as well as an economic perspective: smoking-related diseases like lung cancer 
or COPD (Chronic Obstructive Pulmonary Disease) are extremely expensive to treat, so 
reductions in long-term morbidity would also likely imply considerable cost savings in the long 
run.42-46 However, given the strong assumptions associated with the assessment of future 
mortality and morbidity decline due to the high school smoking ban, and the associated 
uncertainty about the permanency of the effect, both programs to ensure the permanency as well 
as data collection efforts to assess the long-term impact are needed.  
 
Notwithstanding, this study, comprised of a nationally representative sample of over 300,000 
adolescents and young adults from over 100 municipalities and over 4000 schools across all parts 
of Chile between 2000 and 2011, is a very comprehensive study of a country’s national tobacco 
legislation to date. Its findings that high school smoking bans can significantly reduce teenage 
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smoking rates, but fail to address frequent smokers, are relevant policy lessons for both national 
and global health policy makers.  
 
An important limitation of this study is that individuals were not randomly assigned to the 
intervention group (high-school students) and comparison group (university-age). However, we 
would like to emphasize that, except for the high school smoking ban, all provisions of the 2005 
law uniformly affected Chile’s general population (Supplementary Appendix 1, Section 2, Table 
S1.10). Thus, even if the law affected the comparison group, it would have been by a section of 
the law that also affected the high school population.  
 
A further weakness might be found in the fact that the average age of smoking initiation was 
13.2 years in Chile and that older individuals are less likely to start or quit smoking. Hence, 
university-age students—both smokers and non-smokers—may have a lower propensity to 
change their behavior in response to a similar ban. This could have led to an upward bias in the 
effect size estimates. However, in a sensitivity analysis using the general population aged 25-64 
years as a control group, the effect sizes were not significantly higher than when using the 
university aged population as a comparison group. 
 
Another limitation is that no longitudinal individual-level data exist to distinguish between three 
effects that may account for our results: 1) that the ban prevented people from starting smoking, 
2) that the ban made less frequent (or less addicted) smokers to smoke less, and a more 
unexpected effect, 3) that the ban caused smokers to smoke more often. Only a survival analysis 
using individual-level panel data or an analysis of total cigarette consumption adjusting for the 
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days smoked per month among smokers before and after the ban would allow to disentangle 
these effects. Additional data on compliance with the smoking ban at Chilean high schools (akin 
to data provided by Goel et al.47 in India) could have further strengthened our conclusions. 
 
Future studies could explore equity concerns relating to the school smoking ban in Chile, as 
smoking prevalence is often highly correlated with socioeconomic status (SES).48 Targeting light 
smokers largely means targeting high SES smokers who smoke less frequently (and are less 
addicted) than low SES smokers (results available from the authors). Since SES variables in both 
intervention and control group were highly collinear with neighborhood and were subjective 
based on the coding by interviewers, SES variables were omitted from the main analyses. 
Furthermore, a stratification based on SES would not have been meaningful due to the relative 
(as opposed to absolute) scale of the SES variables.  
 
Another limitation was that there were no data on how well schools followed the ban, a potential 
effect modifier. However, interviews with key anti-tobacco advocates and Chilean policy makers 
did not any parallel programs that might have substantially biased the results.  
 
CONCLUSION 
 
This quasi-experimental analysis lends support that the 2005 school smoking ban (enforced since 
2006) helped reduce the smoking prevalence among Chilean high school students, particularly 
among teenagers and light smokers. These results signal to policymakers and school 
administrators that school-smoking bans can be highly effective. Our results send an encouraging 
signal that Chile’s 2013 anti-tobacco legislation, extending the ban to bars, restaurants, and 
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universities, may help in further curbing smoking rates in Chile. But also, both the 2005 and 
2013 tobacco-legislation in Chile offered little help to those in need for (proven-effective) 
cessation counseling and cessation programs.11,12,49 Hence, future policies would benefit from 
including accessible cessation programs, funds for smoke free enforcement in additional public 
spaces, and other provisions to help smokers quit. As a country with roughly seven million 
smokers out of a population of 16 million, Chile needs anti-tobacco policies that are more 
comprehensive than instituting public bans alone. 
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SUPPLEMENTARY APPENDIX 1 
 
CAN BANS BREAK BAD HABITS? AN INTERRUPTED TIME SERIES ANALYSIS OF THE IMPACT OF 
THE HIGH SCHOOL SMOKING BAN ON TEENAGE SMOKING BEHAVIOR IN CHILE, 2000 – 2011 
 
 
Andrea B Feigl1, Joshua A Salomon1, Goodarz Danaei1, Eric L Ding2, Esteban Calvo3 
 
 
S1.1 DATA AND SAMPLING PROCEDURES 
 
Data source 
For the intervention population, we used data from School Population Survey (SENDA-SPS) – a 
biennial, and regionally representative survey on substance abuse and addictive behavior in the 
Chilean school population, including the last grade of primary school (equivalent to 8th grade), 
and the high school population (equivalent of 9th – 12th grade). SENDA-SPS was conducted in 
the fall of every odd year, and data starting in 2001 were included in the analyses.1 Sampling was 
based on a two-stage process: two classes were sampled from strata that were defined at the 
municipality, type of school (public, non-profit, and private), and grade (8th through 12th) level. 
From each class, 20 students were sampled at random. Since the data did not include explicit 
sampling unit and stratum variables, sampling units and strata were recreated (based on the 
survey methodology documents), and complex survey analysis was performed as a sensitivity 
analysis (See below detailed sections). 
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For the comparison population, we used data from the General Population Survey (SENDA-
GPS). SENDA-GPS was conducted in even years, and we included data for 2000-2010.1 The 
SENDA-SPS and SENDA-GPS datasets are publicly available. 
SENDA-GPS employed a three-stage sampling design, first randomly sampling census blocks 
within municipalities. Within these identified sampling blocks, households were selected at 
random, with the number of households sampled proportional to the census block size. 
Household members were selected at random to participate in the study. While stratum and 
cluster unit information were not available (except for 2010), synthetic clusters were created by 
sorting on municipality, year and educational attainment and assigning 15 consecutive 
observations to the same cluster, following the approach described by Jolliffe.2 The results taking 
into account complex survey design are presented as sensitivity analyses. 
The resulting dataset contains three waves before the law (2000-01, 2002-03, 2004-05) and three 
waves after (2006-2007, 2008-09, 2010-11), including different individuals each time, with an 
average sample size of ~50,000 individuals per biennium in SENDA-SPS and ~ 2,300 
individuals in SENDA-GPS per biennium. (See Tables S1.1 – S1.3). 
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Table S1.1: Number of data records in the SENDA-SPS dataset used for the high 
school population. The drop in the total school population between 2009 and 2011 is 
due to widespread student protests and an associated drop in school enrollment. 
Year  12-22 year old HS population* # Municipalities  
Total Chilean school population in 
surveyed municipalities aged 12-22  
2001 58,722 86 825,908 
2003 58,489 86 975,364 
2005 59,881 86 988,149 
2007 52,145 91 968,996 
2009 48,980 99 969,339 
2011 33,509 104 863,886 
*The majority of the HS population is 12-18 years old, only less than 0.2% of all HS students are 
between 
19 and 22 years of age 
 
 
 
 
Table S1.1: Number of data records in the SENDA-GPS dataset used for the university-aged population. 
The number of Chilean municipalities included in the sample and the total general Chilean population in surveyed 
municipalities aged 12-64 years are shown, also. 
Year  12-64 year olds 
19-24 year 
olds  # Municipalities 
Total Chilean population in 
surveyed municipalities aged 
12-64 
2000 44,421 5,466  86 7,779,905 
2002 16,476 1,945  87 8,392,058 
2004 16,166 1,927  87 8,715,567 
2006 17,192 1,937  91 8,876,262 
2008 17,113 1,807 20-24yrs: 1,517 95 8,954,639 
2010 16,000 1,807 22-24yrs: 902  108 9,738,623 
 
 
 
 
Table S1.3: Smoking prevalence in surveyed high school grades between 2000/01 and 2010/11 in 
Chile. 
 
SMOKING 
PREVALENCE 
IN… 
2000/01 2002/03 2004/05 2006/07 2008/09 2010/11 
8th grade 26.4% 24.2% 26.1% 20.7% 19.1% 13.3% 
9th grade 38.1% 33.2% 38.3% 31.0% 30.0% 23.8% 
10th grade 45.4% 42.0% 45.7% 38.0% 36.4% 28.7% 
11th grade 51.1% 47.7% 49.3% 44.2% 40.6% 33.0% 
12th grade 53.9% 51.3% 51.6% 45.6% 43.5% 36.1% 
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Data Structure 
Chile is geographically divided into 15 regions and 346 municipalities. Both the school and 
general population survey are representative at the regional level, but sample only among those 
municipalities with n ≥ 30,000 inhabitants. Both surveys use multi-stage sampling procedures, 
which are described in the paragraphs below. The information on sampling procedures was 
obtained via email communication with data managers and from data manuals associated with 
the datasets. The Spanish text was translated into English, and EL Calvo verified the translation. 
 
a) SENDA school population survey (SENDA-SPS) 
 
SENDA-SPS employed a stratified, probabilistic two-stage sampling procedure. 
The sample was stratified based on municipalities, types of high schools (public, voucher school, 
and private schools), and grade levels (grades 8 - 12).  
 
Thus, the Stratum Sklm is specified at 1,2, …, k municipalities (86 ≤ k ≤ 103), at l=1,..,3 types of 
schools (public, non-profit, or private), and at m = 1, …, 5 grade levels (8th through 12th grade). 
 
From each stratum, 2 classes were sampled. (At each school, students are put into classes of size 
n~=35) based on grade level. All classes were enumerated at the national level, and 2 classes per 
stratum were chosen, with a probability to be chosen proportional to the exact class size. During 
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the second stage, 20 students were chosen at random (and without replacement) from the 2 
sampled classes per stratum. 
 
Therefore, the PSU is ‘classes’. However, even after contacting the data provider, the PSU could 
not be provided for data analysis. The stratum variable was also not provided in the dataset, nor 
was specific information on non-response rates. 
 
Further, while there are survey weights that provide the inverse of the probability of the selected 
individuals to have been chosen at the national level, how these weights were obtained was not 
described in the survey handbook. Therefore, we only used weights in the sensitivity analysis. 
 
Missing an explicit PSU variable, stratum variable, and specific information on individual 
probability weights, the sampling strategy was taken into account as best as possible in the model 
by applying the following procedures: 
 -­‐ Cluster-robust standard errors. The robust variance estimate is also known as the 
Huber/White/sandwich estimate of variance.3 In this specific case, we used a model-agnostic 
robust variance since the model could not be specified to include the psu, stratum, and 
information on the weight variable, the latter of which would have helped in determining the 
more specific variance type. 	  -­‐ The cluster variable was comuna (municipality), as most between-cluster heterogeneity and 
within-cluster homogeneity was expected at the comuna level -­‐ Grade level and type of school were included as covariates in each analysis 
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As a sensitivity analysis, however, a stratum variable was recreated by grouping all observations 
in the same municipality, at the same grade level, and in the same type (private, non-profit, 
public) school. After receiving information on the survey methodology from SENDA in Chile, 
we were also able to establish that the PSU variable coincided with the weight variable (though 
the exact calculations for the weight variable could not be verified). Based on this information, a 
complex survey analysis (for the first stage of the analysis model) was conducted, using the 
svyset command. Single unit standard errors were estimated based on the ‘scaled’ version, where 
the scaling factor is based on the mean of the variances from the strata with multiple sampling 
units for each stratum with one sampling unit.  
 
b) SENDA general population survey (SENDA-GPS) 
 
SENDA-GPS employed a stratified, probabilistic three stage sampling strategy:  
 
1st stage: census block (manzana) sampling, with probability to be picked proportional to its 
population size. (PSU = manzana). 
In order to optimize the selection of census blocks (in order to pick as many small as large 
census blocks in each municipality), the census block-sampling frame was divided into strata 
based on size (where size was a function of the number of houses per census block). 
 
The probability for a census block to be sampled was defined as:  
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𝑝! 𝑖 =    𝑛!𝑀!𝑀!!   
 
where nh corresponds to the number of selected census blocks in municipality h; Mh is the 
number of households in municipality h and Mhi is the number of households in census block i in 
municipality h.  
 
 
2nd stage: sampling of viviendas (households) (SSU). Each household in the sampled census 
blocks has equal probability of being sampled. Sampling was done at random, without 
replacement. 
 
3rd stage: individual selected (at random) per household (if between 12 and 65 years of age). The 
Kish sampling method was followed.  
 
 
Unfortunately, the psu and ssu variables were only available for data starting in the year 2010. 
Therefore, to account for the sampling design as best as possible, by applying the following 
procedures in the main model: 
 -­‐ Cluster-robust standard errors were modeled. The cluster variable was comuna (municipality), 
as most between-cluster heterogeneity and within-cluster homogeneity was expected at the 
comuna level 
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While stratum and cluster unit information were not available (except for 2010), synthetic 
clusters were created as suggested by Jolliffe.2 Since the average cluster number in 2010 was 15, 
synthetic clusters were recreated in the entire control population dataset (19- 65 years) by sorting 
municipality, year, and on educational attainment and then assigning 15 consecutive 
observations to the same cluster. Municipality units were treated as stratum variables. Single unit 
standard errors were estimated based on the ‘scaled’ version. The results of the analysis taking 
into account complex survey design are presented as sensitivity analyses. 
 
MODEL SPECIFICATION 
 
As specified in the manuscript, the goal of this analysis was to estimate the smoking prevalence 
rate ratios (rather than the odds ratios) in the intervention and the control group, to then estimate 
the effect of the high school smoking ban on annual percentage changes of smoking prevalence 
due to the law.  
 
In general, the estimation of prevalence rates ratios (rather than odds ratios) is of interest when 
common outcomes are involved.4 Smoking is one such common outcome of particular public 
(health) interest.  
 
The outcome variables of interest, last-month smoking behavior and heavy smoking are coded as 
a binary (0,1) variable. Thus, several methods to model binomial health outcomes are available: 
the log-binomial model, the robust Poisson model, and direct estimation of prevalence ratios 
from odds ratios 4-6. The latter method is only the preferred method in case of rare diseases. In 
fact, using logistic regression to estimate the adjusted PR in a study with a common binary 
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outcome, is not recommended.7 Since Poisson models are least affected by model 
misspecification4,8, the Poisson model was chosen to model smoking behavior in the Chilean 
high school and university-aged population.  
 
As specified in the introduction and methods section of the paper, the main aim of this analysis 
was to estimate the impact of the high school smoking ban. Before-after ban smoking rates in the 
high school population were compared to before-after smoking behavior in the control 
university-aged population. Since data about the intervention and control population come from 
different surveys, a two-stage model to estimate the impact of the law was applied (see below & 
Figure S1.1). 
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Figure S1.1: Schematic of Time Series Analysis with comparison group using non-linear 
spline modeling. The beta coefficients in the figure correspond to the coefficients in Equation 1. 
The hypotheses that were tested in the analyses are: H0: β2a = β2b; H02: β2a =0; H03: β2b =0. 
Because of the two-stage independent stratified analysis, H0 was tested via a two-sample t-test 
with unequal variances. 
 
2-stage model with time-dependent spline term for trend before/ after 2005 
Stage 0: creation of time-period specific term  
Stage 1: Separate robust Poisson regression models for each intervention and control group 
Stage 2: Two-sample t-test of the β2 coefficients of each model 
 
Stage 1 Regression model: 
Yij = α + β1*timeperiod1i + β2timeperiod2j + β3-n(covariates)ij + ɛij 
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• i… individuals; j… time; ɛ… standard errors clustered and the municipal level (HS) and 
regional level (Uni) 
• 2-stage model (separate models for 2 groups; model “a” for HS group, model “b” for Uni 
group) 
• H01: β2a = β2b (two-sample t-test with unequal variances) 
• H02: β2a = 0  
• H03: β2b = 0 
 
 
… where Y represents the binary smoking variable of interest, for individual i at time j. In the 
first stage, the models (model ‘a’ and model ‘b’) were run separately for each group, since the 
data from SENDA-SPS and SENDA-GPS had different weight variables and adjustment factors 
to ensure the representativeness of the results. The second stage of the model was a two-sample 
mean comparison test with unequal variances. The hypotheses that were tested in the analyses 
were: H01: β2a = β2b; H02: β2a =0; H03: β2b =0. H01 was tested via a two-sample t-test with unequal 
variances, and H02 and H03 were tested via the significance test of the coefficient in each model.  
 	  
Table S1.4: Values for time period variable in first stage Poisson regression 
 2000/01 2002/03 2004/05 2006/07 2008/09 2010/11 
timeperiod1 1 3 5 7 9 11 
timeperiod2 0 0 0 2 4 6 
 
 
 
 
 
Table S1.5: Covariates and specification of first stage of regression analysis 
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 High School Population University-Aged Population 
Covariates Age, sex, age*sex, school grade, region, school type Age, sex, age*sex, region, SES 
Specification Robust standard errors clustered at the district level 
Robust standard errors clustered at the district 
level 
 
 	  
Detailed Results - Sensitivity Analyses 
 
As described in the methods section, several sensitivity analyses were carried out for both 
outcome variables (smoking prevalence and heavy smoking). The results of the sensitivity 
analysis are presented in the appendix tables.  
(1) Including all 19-24 year olds in the control population (the base-case analysis excluded those 
from the control who would have been exposed to the intervention while in high school), we 
found that the effect size estimate of the impact of the law on curbing smoking prevalence in 
high school students was lower and no longer significant (RR 95% CI: 0.96, 1.00; p=0.0987). (2) 
When examining the pre- and post-law prevalence changes of marijuana use (a popular 
recreational drug in Chile: in 2010-11, 9.72% of HS students, and 6.03% of the control 
population responded that they used marijuana in the past month), past 30-day marijuana use 
after 2005 increased by 14% (95% CI: 11%, 18%; p<0.0001) annually in the HS population 
versus the control population. (3) Further sensitivity analyses including only those municipalities 
included in all years yielded identical effect size estimates as the main analysis (Table S1.6).  (4) 
When including only those with a high school diploma in the control population, the effect size 
increased to a -4.5% (CI: -1.3%, 7.5%; p=0.0056) annual prevalence decline in the intervention 
versus the control population. (5-6) Adjusting for past month alcohol prevalence, religion, and 
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paternal education (in the HS population) led to a slight increase in the effect size estimate 
(showing a 4.8% annual post-law relative prevalence decline). (7-8) The sensitivity analyses 
using the survey weights or the re-created stratum and PSU variables in addition to the weights 
showed an annual decline of 3.8% of post-law smoking prevalence in the HS versus the control 
population. However, since the stratum and PSU variables were not explicitly included in the 
dataset (but rather, recreated based on the survey methods document), these analyses served as 
sensitivity analyses only (Table S1.7). Nevertheless, the effect size estimates in the main and the 
weighted analysis were close (showing a 2.9% vs 3.8% annual smoking prevalence decrease). 
Specification tests to assess model fit of two non-nested models require the same weights to be 
used in both models9, hence no applicable specification test to contrast the goodness of fit of the 
main versus the survey-weighted model was available. (10) In another sensitivity analysis, using 
the missing indicator method, results remained unaltered with respect to effect sizes and standard 
error size compared to the main model. Lastly, the 2005 ban had the greatest impact in schools in 
high SES municipalities in the Greater Metropolitan Region of Santiago (results not shown).  
With regard to the sensitivity analyses for the impact of the law on heavy smoking, sampling-
weight and complex survey adjusted models (results not shown) also revealed no significant 
difference in heavy smoking prevalence change before and after the law in control versus 
comparison groups. This result remained robust when stratifying by grade levels, also (Table 
S1.9). 	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Table S1.6: Sensitivity analyses testing the impact of the 2005 law on smoking prevalence. The presented 
RRs represent the annual dose response decrease in smoking prevalence. The first stage model of the high school 
population was adjusted for age, sex, region, school-type, course, and sex*age. The first stage model of the 
university-aged population included age, sex, region, SES, survey method, and sex*age. (CI = Confidence 
Interval; RR = Relative Risk). 
	  	  	   	  
Population and Study Period 
(1) Controls 
include 19-24 yr 
olds in 2008-
2011 
(2) Marijuana 
Prevalence as 
main outcome 
(3) Only 
municipalities 
measured in every 
survey year 
(4) Only those 
with at least HS 
diploma in the 
control 
population 
Stage 1a: HS Group (Targeted Intervention Population) 
Pre-Policy Annual Prevalence 
Rate change 
1.01 (1.00, 1.01) 
p=0.014 
0.985 (0.970, 
1.001) p=0.065 
1.01 (1.00, 1.01) 
p=0.025 
1.01 (1.00, 1.01) 
p=0.014 
Post-Policy Annual Prevalence 
Rate change 
0.932 (0.927, 
0.937) p<0.001 
1.06 (1.05, 1.07) 
p<0.001 
0.931 (0.926, 0.936) 
p<0.001 
0.932 (0.927, 
0.937) p<0.001 
Difference in Prevalence change 0.926 (0.917, 0.934) p<0.001 
1.08 (1.05, 1.10) 
p<0.001 
0.925 (0.927, 0.934) 
p<0.001  
0.926 (0.917, 
0.934) p<0.001 
Stage 1b: University-aged Group (Comparison Population) 
Pre-Policy Annual Prevalence 
Rate change 
1.01 (1.00, 1.02) 
p=0.019 
1.04 (0.986, 1.09) 
p=0.167 
1.01 (0.998, 1.02) 
p=0.112 
1.00 (0.988, 1.02) 
p=0.666 
Post-Policy Annual Prevalence 
Rate change 
0.956 (0.946, 
0.966) p<0.001 
1.00 (0.965, 1.05) p 
= 0.850 
0.962 (0.951, 0.973) 
p<0.001 
0.973 (0.954, 
0.992) p=0.005 
Difference in Prevalence change 0.943 (0.924, 0.962) p <0.001 
0.970 (0.899, 1.05) 
p=0.437 
0.953 (0.932, 0.974) 
p<0.001 
0.969 (0.940, 
1.00) p=0.666 
Stage 2: Two sample mean-comparison test 
Intervention Effect 
0.982  
(0.960, 1.00) 
p=0.0987 
1.14  
(1.11, 1.18) 
p<0.0001 
0.971  
(0.948, 0.995) 
p=0.0176 
0.955  
(0.925, 0.987) 
p=0.0056 
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Table S1.7: Sensitivity analyses testing the impact of the 2005 law on smoking prevalence. The 
presented RRs represent the annual dose response decrease in smoking prevalence. The first stage model 
of the high school population was adjusted for age, sex, region, school-type, course, and sex*age. The 
first stage model of the university-aged population included age, sex, region, SES, survey method, and 
sex*age and age. (CI = Confidence Interval; RR = Relative Risk). 
Population and Study 
Period 
(5) Additional 
covariates: Past month 
alcohol prevalence, 
religion 
(6) Additional covariates: 
Past month alcohol 
prevalence, religion, 
paternal education 
(7) Main results 
with sample 
weights 
Stage 1a 
HS Group (Targeted Intervention Population) 
Pre-Policy Annual 
Prevalence Rate change 1.01 (1.00, 1.01) p=0.037 1.00 (0.999, 1.01) p=0.111 
1.01 (1.00, 1.01) 
p=0.001 
Post-Policy Annual 
Prevalence Rate change 
0.932 (0.927, 0.937) 
p<0.001 
0.934 (0.929, 0.939) 
p<0.001 
0.931 (0.926, 
0.937) p<0.001 
Difference in Prevalence 
change 
0.927 (0.918, 0.936) 
p<0.001 
0.930 (0.922, 0.939) 
p<0.001 
0.923 (0.914, 
0.932) p<0.001 
Stage 1b 
University-aged Group (Comparison Population) 
Pre-Policy Annual 
Prevalence Rate change 1.00 (0.993, 1.01) p=0.570 1.00 (0.993, 1.01) p=0.570 
1.01 (0.987, 1.03) 
p=0.541 
Post-Policy Annual 
Prevalence Rate change 
0.977 (0.966, 0.987) 
p<0.001 
0.977 (0.966, 0.987) 
p<0.001 
0.965 (0.946, 
0.984) p=0.001 
Difference in Prevalence 
change 
0.974 (0.955, 0.992) 
p=0.005 
0.974 (0.955, 0.992) 
p=0.005 
0.960 (0.924, 
0.996) p=0.029 
Stage 2: Two sample mean-comparison test 
Intervention Effect  
0.952 
(0.932, 0.973) 
p<0.0001 
0.956 
(0.936, 0.976) 
 p<0.0001 
0.962 
(0.926, 0.999) 
p=0.049 	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Table S1.8: Sensitivity analysis (8) of impact of smoking law on high school smoking rates using complex 
survey design. For stage 1 of the analysis in the intervention group, survey strata were recreated grouping 
municipality, type of school, and grade level. Primary survey units (PSUs) were recreated based on the survey 
weight variable, and standard errors in strata with only one PSU were scaled based on the average of variances 
from the strata with multiple sampling units. For stage 1 for the control group, since stratum and PSU variables 
were missing, clustering was induced using the Joliffe approach, and each municipality was treated as a separate 
stratum. Again, standard errors in strata with only one PSU were scaled based on the average of variances from 
the strata with multiple sampling units. 
 
  
Stage 1a: High School Group PR of prevalence change (95% CI) 
RR of Difference 
in Prevalence 
change 
RR of Difference in post-
policy prevalence change 
Pre-Policy Annual Prevalence Rate 
change 
 
1.01 (1.01, 1.01)  
p < 0.001 0.923 (0.916, 
0.930) p<0.001 
0.962 (0.928, 0.997) p=0.0340 
Post-Policy Annual Prevalence Rate 
change 
 
0.931 (0.927, 
0.935) p<0.001 
Stage 1b: University-aged Group   
Pre-Policy Annual Prevalence Rate 
change 
 
1.01 (0.989, 1.02) 
p=0.489 
 0.959 (0.926, 0.993) p=0.02 
Post-Policy Annual Prevalence Rate 
change 
0.931 (0.927, 
0.935) p<0.001 
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Table S1.9: Results from the 2-stage marginal fixed effects Poisson model testing the impact of the 2005 
law on heavy smoking for each high school grade. RRs represent the annual dose response in smoking 
frequency. The first stage model of the high school population was adjusted for age, sex, region, school-type, 
course, and sex*age. The first stage model of the university-aged population included age, sex, region, SES, 
survey method, and sex*age. (CI = Confidence Interval; RR = Relative Risk). 
  8
th grade 9th grade 10th grade 11th grade 12th grade 
 Stage 1a: HS Group (Targeted Intervention Population) 
Pre-Policy Annual 
change in frequency 
0.939 (0.889, 
0.990) p=0.020 
1.01 (0.977, 
1.043) p=0.591 
0.976 (0.946, 
1.01) p=0.122 
0.969 (0.940, 
0.998) p=0.036 
0.952 (0.927, 
0.978) p<0.001 
Post-Policy Annual 
change in frequency 
0.918 (0.893, 
0.943) p<0.001 
0.927 (0.914, 
0.940) p<0.001 
0.916 (0.904, 
0.929) p<0.001 
0.922 (0.911, 
0.935) p<0.001 
0.929 (0.926, 
0.943) p<0.001 
Difference in change in 
frequency 
0.978 (0.912, 
1.05) p=0.534 
0.919 (0.883, 
0.956) p<0.001 
0.939 (0.903, 
0.977) p=0.002 
0.952 (0.918, 
0.988) p=0.01 
0.975 (0.940, 
1.01) p=0.190 
 Stage 1b: University-aged Group (Comparison Population) 
Pre-Policy Annual change 
in frequency 0.992 (0.959, 1.03) p=0.669 
Post-Policy Annual 
change in frequency 0.953 (0.938, 0.969 p<0.001 
Difference in change in 
frequency 0.986 (0.938, 1.036) p=0.580 
 Stage 2: Two sample mean-comparison test 
Intervention Effect 
1.02  
(0.937, 1.06) 
p=0.675 
0.957  
(0.901, 1.02) 
p=0.1447 
0.978 (0.921, 
1.04) p=0.458 
0.991  
(0.935, 1.05) 
p=0.7672 
1.02  
(0.959, 1.08) 
p=0.5995 	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Additional comments on limitations 
An important limitation of this study is that individuals were not randomly assigned to the 
intervention group (high-school students) and comparison group (university-age). However, we 
would like to emphasize that, except for the high school smoking ban, all provisions of the 2005 
law uniformly affected Chile’s general population (Supplementary Appendix 1, Section 2, Table 
S1.10). Thus, even if the law affected the comparison group, it would have been by a section of 
the law that also affected the high school population. Therefore, our analysis addresses the 
differential impact of the law on high school smoking frequency as attributable to the smoking 
ban specifically and differentially targeting the Chilean high school population. 	  
 
S1.2 CHILE’S EDUCATIONAL SYSTEM 
 
The educational system in Chile involves both public and private (for profit and not-for-profit) 
schools, and is divided into the following categories: 1) Preschool (educación parvularia), which 
compares to kindergarten and is attended by children under six years of age, 2) Primary/ 
Elementary school (educación básica) (for pupils age six to 14), and 3) Secondary/High school 
(educación media), which consists of four grades and offers students a choice of two types of 
diplomas (the general science-liberal arts diploma, or the vocational-technical diploma (which 
combines the general studies program with preparation for a trade). Public schools are 
completely free to attend. Instead of attending public schools, students can choose to attend 
private schools, and the government will pay the attendance fees at these schools via a voucher: 
however, the government matches the exact same amount as it would cost to attend public 
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schools. The majority of private for-profit schools match the attendance costs of public schools. 
A small minority of elite schools (enrolling roughly 7% of the Chilean school population) has an 
attendance cost of about five times the value of the vouchers and in addition, have extremely 
stringent enrollment criteria. Since 2003, a constitutional reform mandated school attendance for 
twelve years, but at the same time, also guaranteed that education (in public schools) would be 
free. While school enrollment between the ages of 6 and 14 is close to 100%, this number drops 
off among older students; for example, only just over 70 percent of 17-year olds attend school in 
Chile, despite the fact that since 2003, 12 years of schooling are mandatory. 
 
S1.3 CHILE’S TOBACCO LAWS 
 
In Chile, smoking is the 4th leading cause of mortality and morbidity with 1 out of 11 deaths 
attributed to smoking.10 Lung cancer mortality is increasing, especially in women, with 6 out of 
the 10 leading causes of death for women attributed to smoking.11 The associated effects of 
tobacco smoking contribute to substantial costs. A study by Martinez-Gutierrez and colleagues 
calculated tobacco-attributable yearly direct costs (in pesos) in two hospitals in Santiago, Chile.12 
These direct costs tap into outpatient care, emergency care, hospitalizations, and medicine and 
health supplies and were estimated at $80,432 for ischemic heart disease, $285,230 for chronic 
obstructive pulmonary disease (COPD), and $70,420 for lung cancer. In addition to the economic 
burden due to associated medical cost, smoking substantially contributes to disability days and 
years of potential life lost due to premature death. 
 
 Aware of the public health and economic concerns, the Chilean government’s efforts in 
addressing tobacco policy have been modest. In 1995, almost half a century after the landmark 
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paper by Sir Richard Doll on the causal link between smoking and lung cancer13, Law nº 19.419 
was introduced with aims to zone smoking and non-smoking areas in restaurants, hotels, and 
other establishments6. However, its provisions were weak and faced strong opposition from the 
tobacco industry. After enactment of Law 19.419, the number of smokers in Chile continued to 
grow. 
 
Ten years later, Chile ratified the FCTC on June 13th, 2005. The law went into effect on 
September 11th, 2005, and provided momentum for legislation that would modify Law 19.419. 
The new Law 20.105 took effect in 2006 with the following key provisions: (1) tobacco ads were 
to be confined to points of sale; (2) the legal smoking age was elevated to 18 years of age; (3) 
information on the health risks of smoking as well as an annual report on the composition of 
tobacco products were made available to the public; (4) smoke-free environments were to be 
established, and (5) there would be sanctions for non-compliance with the new regulations. 
 
However, the 2006 law fell short of several FCTC recommendations. Most importantly, 
however, it only created 100% smoke free spaces in public schools, but failed to do so in 
restaurants, bars, and universities. Particularly, the major shortfalls of the law as it relates to the 
FCTC are as follows: 
 
Article 6 (Price and Tax Measures to reduce the demand for tobacco): Neither the 2005 law nor the 2011/12 
amendment included the enforcement of tobacco taxes which is shown to be one of the most effective strategies in 
decreasing smoking rates, particularly among the poor and young. 
 
Article 8 (Protection from exposure to tobacco smoke): The current law only mandates partially smoke-free zones 
(in schools and in restaurants). Compliance is low, and fines are not imposed. The only 100% smoke-free zones in 
Chile are public schools. 
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Article 11 (Packaging and Labeling of Tobacco Products): The Chilean Ministry of Health has only run one 
national anti-smoking campaign, and there are no official educational and tobacco awareness campaigns in schools. 
In addition, anti-smoking labels on cigarette packs only focused on one adverse health consequence of smoking: 
impotence. Among the five most severe smoking-related health consequences, knowledge about impotence provides 
the least motivation for smoking cessation.14-16 Also, this current campaign only targets men; in Chile, the highest 
smoking rates are found in women of childbearing age (43%; ENS 09/10), endangering both current and future 
generations with this risky behavior. 
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Table S1.10: The 1995 and 2005 Chilean Tobacco laws in comparison (Articles in Bold in 
2005 constitute a change from the 1995 law; Articles highlighted in orange represent the 
components of the 2005 that were very weakly implemented). 
Article 1995 Law 2005 Law 
1° Definition of activities related to 
tobacco control 
Definition of activities related to tobacco 
control 
2° No advertising aimed at minors less 
than 18 years of age 
No advertising except at points of sale 
3° Tobacco sales only allowed at ages 16 
or above 
Tobacco sales only allowed at ages 18 or 
above 
4° Awareness of health risks (no specific 
campaigns) 
Public Health Campaigns: public ads, 
campaigns, and health labels on cigarette 
packages 
5° Tobacco education programs in colleges Tobacco education programs in colleges 
6° Authority of Health services Information about cigarette composition 
on an annual basis, made available freely 
online 
7° Prohibition of smoking in public places Tobacco free environments 
8° Failure to comply with the tobacco law 
constitutes an offense 
Sanctions if failure to comply: much 
stricter and with higher fines 
9° Local Police Enforcement of Sanctions Local Police Enforcements of Tobacco 
Regulations 
10° Individual Responsibility Individual Responsibility 
11° Public Health Services act as part of 
legal processes 
Public Health Services act as part of legal 
processes 
12° Legal enforcement and enactment of the 
law provisions 
Legal enforcement and enactment of the law 
provisions 
13°  Prevention of Smoking Risk Factors 	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ABSTRACT 
 
 
Background. High body mass and blood pressure are two of the leading risk factors contributing 
to the burden of disease in South Africa. Long-term effects of HIV and ART on adiposity and 
blood pressure are not well understood, and direct comparisons of risk factor trajectories in HIV- 
versus HIV+ populations are rare. 
 
Methods.  In 2003 and 2010, height, weight, and blood pressure were recorded in a study 
population (n=505) in KwaZulu-Natal, South Africa, a region with high HIV burden (30% adult 
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prevalence). We modeled change in BMI and blood pressure over time in HIV- individuals 
(n=315), seroconverters (n=32), HIV+ patients not on ART (HIV+ART–; n=52), HIV+ patients on 
ART for 0–<2 years as of 2010 (HIV+ART0–<2 yrs; n=18), patients on ART for 2–5 years 
(HIV+ART2–5yrs; n=44), and a subgroup with unknown HIV status (n=44).  Longitudinal 
differences-in-differences in BMI and blood pressure were assessed for groups in comparison to 
the HIV- population. Uniquely, our study included weight and BP measurements at least one year 
prior to ART among eventual ART users in the sample.  
 
Findings. Between 2003 and 2010, BMI increased significantly in the HIV- group, by 0.874 
kg/m2 (95% CI 0.339 to 1.41; p=0.001), to 30.4 kg/m2. Relative to this change, BMI decreased 
by –5.21 kg/m2 (95% CI –7.53 to –2.90; p=0.001) in the HIV+ART0-<2yrs group, and by –1.35 
kg/m2 (95% CI -2.89, 0.189; p=0.086) in the HIV+ART2–5yrs group. Notably, the decrease in BMI 
was significantly greater in the HIV+ART0-<2yrs versus the HIV+ART2–5yrs group (p=0.005).  
Overall, no major difference-in-differences in SBP were observed between 2003 and 2010, 
except for the HIV+ART– vs HIV- group. Specifically, SBP dropped from 130.4 mmHg (95% CI 
125.0 to 135.0) to 123.5 mmHg (95% CI 118.2 to 128.9) in the HIV+ART- group, resulting in a 
HIV+ART– vs HIV- DID in SBP of  –7.55 mmHg (95% CI –13.2 to –1.90; p=0.009). 
 
Interpretation. Short-term ART (0–<2 years) was associated with a larger weight loss compared 
with no or long-term ART. Once on ART for two or more years, individuals ‘caught up’ on 
weight gain with the HIV- reference population. Such a longitudinal finding of parallel 
trajectories of short-/long-term ART users and HIV+ and HIV- groups have, to our knowledge, 
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never been reported before. Our results showcase the importance of health system readiness to 
address the burgeoning double burden of disease in South Africa. 
	  
 
  
	   59 
INTRODUCTION 
 
South Africa, with a HIV prevalence of 25.2% among 25-49 year olds1, is the country with the 
largest HIV+ population in the world (6.4 million, out of a population of 52.3 million, in 20122,3). 
In 2011, HIV/AIDS was the number one cause of years of life lost (YLL) in South Africa4, and 
the 7th leading cause of death overall.5 Extensive ART rollout has been underway since 2004, 
and even the poorest and hardest hit communities in rural KwaZulu-Natal (South-East South 
Africa) provided ART to over 31% of those in need in 2011.6  
Whilst South Africa better controls the HIV-epidemic7, the chronic disease burden is 
increasing.8-13 In 2010, high body mass index (BMI) and blood pressure (BP) were the top two 
and three risk factors contributing to the burden of disease in South Africa.4 Cerebrovascular 
diseases (CVDs), heart disease, and diabetes were the number three to five largest killers in 
2011, respectively.5  
Although CVD risk factors affect HIV-negative and HIV-positive populations alike8,9, little is 
known about the modifying effect of ART on CVD risk factors, particularly in low-income 
settings. A recent meta-analysis of cardio-metabolic traits in HIV-positive and HIV-negative 
populations in Sub-Saharan Africa (SSA) concluded that HIV infection was associated with both 
lower systolic and diastolic blood pressure, but evidence on the effect of ART on blood pressure 
was largely lacking.14 Our own literature revealed additional cross-sectional evidence that pre-
ART weight was a predictor of onset of diabetes on ART15, that ART was associated with non-
HIV related, chronic morbidity16, and that ART was associated with increased central fat (a 
cardio-metabolic disease marker) and reduced peripheral fat.17 We were unable to identify 
longitudinal studies with a HIV- control group and that spanned both long periods before and 
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after ART rollout. Nonetheless, such population-level evidence is of critical importance, as it is 
plausible that HIV and ART affect CVD risk factors via weight gain among individuals on ART, 
survival benefit of ART, chronic HIV-induced inflammation, and other ART side effects.  
To address this research gap, our study assessed the effect of HIV and the modifying effect of 
ART on body mass and blood pressure in rural KwaZulu-Natal between 2003 and 2010, with the 
two following advantages over similar studies in this field: 1) we include a HIV- group to 
account for the secular trend in risk factors, and 2) the first time point pre-dates ART rollout well 
over one year for all participants, serving as a unique baseline measure. 
 
METHODS 
 
 
Data source 
Nested within a longitudinal, population-based HIV surveillance study, surveys on height, 
weight, and blood pressure were conducted both in 2003/04 and 2010 in rural umKhanyakude in 
KwaZulu-Natal, South Africa, where adult HIV prevalence was close to 30% in 2010.6 The 
survey data from these two rounds are linked at the individual level. The 2003 survey antedated 
the large-scale rollout of ART , which started in August 2004 in this community. The 2010 
survey took place against the background of widespread ART coverage of 24.7%.6 The surveys 
are described in detail elsewhere.8,9 Individuals were eligible for HIV testing and weight, height 
and blood pressure measurement if they were residents in the Africa Center’s defined geographic 
surveillance area (DSA). In 2003/4, the eligible age range was 25-49 years for women, and 25-54 
years for men; in 2010, the eligible age range for the HIV, BMI, and BP survey was >15 years of 
age.  
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Household membership was self-defined on the basis of links to other members.18,19 HIV-
infected participants on ART were all enrolled at 16 primary healthcare (PHC) clinics in the 
Hlabisa subdistrict of umKhanyakude. ART guidelines have indicated that treatment should be 
initiated at CD4 cell counts < 200 cells/µl between 2004 and 2010, the timeframe of this study.  
Study population for weight and blood pressure measurements 
In 2003, 2111 eligible individuals within the DSA completed weight, height, and blood pressure 
measurements as part of a WHO STEPS survey.20 At the start of the second survey round in 
2010, 306 of the original population had died, 11 persons had become very ill, and 335 had out-
migrated. Of the remaining 1,459 participants, 582 refused all questions or did not fully complete 
the 2010 demographic survey; 283 did not consent to weight, height, and BP measurements in 
2010, and 90 had faulty BMI or BP measurements. Thus, 505 individuals had survey, BMI, and 
BP measurements in 2003 and 2010 (Figure 2.1). These individuals constitute the main, 
complete case study population.  
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Figure 2.1: Study Population. 2111 individuals had both BMI and blood pressure measurements in 2003.  This population was 
comprised of females 25-49yrs and males 25-54 yrs who lived in the ACDIS catchment area, were residents, were visited by a 
fieldworker, and completed the full demographic survey, in addition to the WHO STEPS survey which included BMI and BP 
measurements. 505 individuals had survey, BMI, and BP measurements both in 2003 and 2010. These individuals constitute the 
main, complete case study population. For the IPW sensitivity analyses, baseline information of all individuals except those who 
died and were very sick was used to calculate inverse probability weights. 
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Measurements 
HIV status was assessed by enzyme-linked immunoabsorbent assay (ELISA) of EDTA anti-
coagulated blood samples in the Africa Centre virology laboratory, using HIV-1/HIV-2 ELISA. 
Every first positive test was confirmed by a second test. None of the subjects included in the 
study had discordant HIV test results. Height, weight, and blood pressure were measured 
following the WHO STEPS protocol.20 Blood pressure was taken three consecutive times, and 
the averages of the second and third measurements were used to estimate SBP and DBP. 
Underweight was defined as a BMI <18.5 kg/m2, normal weight was 18.5 ≤ BMI <25, and 
overweight and obesity as a BMI 25 to <30, and ≥30, respectively. Stage 1 hypertension was 
defined as Systolic Blood Pressure (SBP) ≥140mmHg and (SBP) < 160 mmHg or Diastolic 
Blood Pressure (DBP) ≥ 90 mmHg, and stage 2 hypertension as SBP≥160mm Hg or DBP≥100 
mmHg. 	  
Statistical Analysis 
The dependent variables for all models were BMI, SBP, and DBP. The exposures of interest 
were HIV status and (length of) ART use. We modeled change in BMI and blood pressure over 
time in HIV-negative individuals, seroconverters, HIV-positive patients not on ART 
(HIV+ART), HIV-positive patients on ART for 0–<2 years (HIV+ART0–<2 yrs), HIV on ART for 
2–5 years (HIV+ART2–5 yrs), and a subgroup with unknown HIV status. Difference-in-differences 
in body mass and blood pressure between 2003 and 2010 in all subgroups were assessed with 
reference to the HIV- group. We adjusted our analyses for baseline levels of potential 
confounders, which were age (continuous), sex, and geographic sampling area.  
We conducted an IPW (Inverse Probability Weighting) analysis to account changes	  in	  the	  
distribution of population characteristics in the different comparison groups due to loss to follow 
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up between 2003 and 2010 (2111 versus 505 participants). Baseline information on all 
individuals except those who died and were very sick was used to compute stabilized inverse 
probability-of-censoring weights (IPCWs).21 The IPCW method assigns a weight to each non-
censored individuals and allows them to ‘represent’ those who have been lost to follow-up after 
adjusting for observed patient characteristics at baseline.22-24 Censoring weights were estimated 
using age (continuous), sex, HIV (treatment) status, education, wealth quintile, geographic 
sampling area, and household assets.  
We tested the robustness of the complete case analysis with several sensitivity analyses. First, we 
included information on those who died and fell ill to calculate the probability weights. For 
censoring weights, death and severe illness are often regarded as extreme events. Characteristics 
of individuals who die or are severely ill might therefore not be comparable to the characteristics 
of those who remain in the population. However, since the study population is a high HIV 
prevalence population, these conventional assumptions might not hold. Therefore, we conducted 
a sensitivity analysis that included baseline information on those who died and fell severely 
ill.25,26  
To test for the sensitivity of our results to individuals with very high or very low weight, we 
excluded those with BMI≥50. As BMI might be an independent risk factor for high BP, we also 
adjusted for BMI at baseline (assuming no collider bias27). Further IPCWs included fewer 
covariates to calculate the probability weights: age, sex, general health, and the asset indicator at 
baseline. The results for the effects of HIV and ART on DBP over time are presented as 
sensitivity analyses, since SBP and DBP are generally highly correlated. All analyses were 
performed using STATA 13.   
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RESULTS 
 
 
Baseline Characteristics 
In 2003, the mean age of the complete case, main study population was 39.5 (SD: 7.2) years, and 
mean BMI was 29.0 kg/m2 (SD: 7.2). 13.1 percent of respondents were in the highest asset index 
quintile, 23.6 percent had completed 2ary or higher education, and 37.1 percent reported to be in 
very good or excellent health. Baseline SBP was 126.6 mmHg (SD: 20.2), and DBP was 80.6 
mmHg (SD: 13.2) (Table 2.1). 
We found several differences in the baseline characteristics between the ‘2003 only’ and the 
‘complete case’ population (Table 2.1). Most notably, the complete case population was older, 
heavier, had higher blood pressure, and had a higher percentage of females. The complete case 
population was also overall poorer and less educated, had lower self-reported health, and had a 
higher prevalence of HIV- individuals (Table 2.1).  
  
	   66 
Table 2.3: Baseline characteristics. This table shows unadjusted sex, age, weight, height, BMI, SBP, DBP, HIV status, 
educational status, self-reported health status, and asset index characteristics of the following populations: The baseline 
cohort population (n=2111); the ‘2003 only’ population (n=1289); the characteristics of those who died or fell very ill 
(n=317); and the complete case population (n=505). The ‘2003 only’ population includes those who succesfully completed 
the 2003 survey, but outmigrated by 2010, prematurely completed the 2010 demographic survey, did not consent to 
biometric measurements in 2010, and had faulty biometric measurements in 2010. Note that those who died or fell very sick 
by 2010 were not included among the 2003 only population. The complete case population represents those with full 
measurements in both 2003 and 2010. 
 
Baseline 
Cohort 
(n = 2111) 
2003 only, 
excluding dead 
& very sick 
(n=1289)   
Died & Very 
Sick 
n=317 
Complete Case 
population 
(n=505) 
Years of age (SD) 37.8  (7.3) 37.0 (7.1) 38.1 (7.7) 39.5 (7.2) 
HIV- 39.0 (7.2) 38.5 (7.3) 42.1 (7.8) 40.8 (7.0) 
HIV+ 36.0 (7.2) 35.7 (6.7) 36.6 (7.4) 38.0 (7.6) 
HIVunknown 36.5 (7.1) 36.2 (6.9) 37.8 (7.4) 38.0 (7.0) 
Weight, kgs (SD) 73.8 (18.9) 75.3 (19.3) 69.3 (18.7) 75.0 (18.8) 
HIV- 74.8 (18.7) 75.3 (19.0) 71.0 (16.2) 75.9 (19.0) 
HIV+ 69.0 (17.9) 70.8 (19.5) 66.9 (18.3) 69.4 (18.4) 
HIVunknown 75.6 (19.1) 77.0 (19.3) 71.3 (20.0) 76.1 (18.1) 
BMI (SD) 28.0 (7.4) 28.5 (7.5) 26.0 (7.4) 29.0 (7.2) 
HIV- 28.4 (7.4) 28.5 (7.5) 26.5 (6.5) 29.4 (7.2) 
HIV+ 26.3 (7.2) 27.0 (7.8) 25.6 (7.7) 27.1 (6.8) 
HIVunknown 28.6 (7.4) 29.1 (7.4) 26.3 (7.6) 29.4 (7.3) 
SBP  (SD) 124.9 (19.0) 124.7 (18.0) 123.7 (22.1) 126.6 (20.2) 
HIV- 126.9 (19.4)  126.3 (18.5) 131.9 (21.1) 127.8 (20.9) 
HIV+ 122.4 (17.8) 122.6 (15.5) 119.9 (19.7) 126.2 (20.4) 
HIVunknown 124.1 (19.1) 124.1 (18.3) 124.1 (24.3) 125.9 (19.1) 
DBP (SD) 79.4 (12.5) 79.29 (12.0) 79.2 (13.7) 80.6 (13.2) 
HIV- 79.7 (12.8) 79.0 (12.3) 82.4 (13.6) 81.0 (13.5) 
HIV+ 78.6 (11.8) 79.1 (11.0) 77.6 (12.7) 79.4 (12.8) 
HIVunknown 79.4 (12.4) 79.5 (12.0) 79.6 (14.5) 80.5 (12.9) 
Sex (female, %) 68.7 66.1 57.1 81.8 
HIV- 66.1 62.4 36.7 79.9 
HIV+ 68.9 69.6 62.1 75.3 
HIVunknown 71.2 68.2 61.5 88.5 
Asset Index (% in highest quintile) 19.1 22.4 15.8 13.1 
HIV-  16.5 18.4 18.3 15.2 
HIV+ 14.5 18.5 12.9 15.4 
HIVunknown 24.4 27.8 18.0 23.6 
Education (% 2ary or higher) 34.0 38.9 29.0 23.6 
HIV- 28.2 32.8 20.0 20.5 
HIV+ 31.3 35.2 30.0 24.7 
HIVunknown 41.3 46.3 32.5 28.2 
Health (% Very good or excellent) 37.1 39.7 31.9 34.3 
HIV- 36.2 39.3 35.0 31.4 
HIV+ 35.2 38.8 29.3 35.3 
HIVunknown 39.2 40.4 33.3 38.5 
HIV status (%)     
HIV- 40.3 40.7 18.9 52.3 
HIV+      20.9 17.2 44.2 16.8 
HIVunknown 38.8 42.2 36.9 30.9 
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Further examining the baseline differences between the HIV subgroups in the complete case 
population, we found that age differed significantly among the four HIV status groups, with the 
highest age in the HIV- group (40.2 years, SD: 7.2) and the lowest age in the HIV+ART- group 
(37.3 years, SD: 7.1) (Table S2.1). BMI differed significantly among subgroups: it was highest 
in the HIVunknown group (30.1kg/m2, SD 7.0), and lowest in the HIV+ART+ group (27.2, SD: 7.1). 
Among those on ART, the average time on ART was 2.5 years (SD: 1.4) between 2004 and 
2010. 29% of ART users were on ART for 0-<2 years between 2004 and 2010. CD4+ count 
(measured just prior to ART initiation) was 136.5 (SD: 78.7) for all subjects who initiated ART. 
Gender composition, SBP, and DBP at baseline did not differ significantly between HIV-status 
groups (Table S2.1). The minimum elapsed time between the first BMI and BP measurement and 
ART initiation was 1.2 years; the maximum time between these two measurements was 7.2 years 
(Figures S2.1-S2.3). The average time elapsed between the first BMI and BP measurement and 
ART initiation in the HIV+ART0–<2yrs group was 6.0 years (SD: 0.6) years, and 3.5 years (SD: 
1.0) years in the HIV+ART2–5 yrs group. 
 
Effect of ART and HIV on change of BMI and Blood Pressure 
Between 2003 and 2010, BMI increased significantly in the HIV- group, by 0.874 kg/m2 (95% CI 
0.339 to 1.41; p=0.001), to 30.4 kg/m2. BMI significantly decreased by -4.34 kg/m2 (95% CI -
6.58 to -2.10; p<0.001) in the HIV+ART0-<2yrs population, to 25.9 kg/m2 in 2010. All other groups 
experienced non-significant changes in BMI between 2003 and 2010 (Table 2a). 
Relative to this change, BMI decreased by –5.21 kg/m2 (95% CI –7.53 to –2.90; p=0.001) in the 
HIV+ART0-<2yrs group, and by –1.35 kg/m2 (95% CI -2.89, 0.189; p=0.086) in the HIV+ART2–5yrs 
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group. The relative changes in BMI between HIV+ART0-<2yrs and HIV+ART2–5 yrs were 
significantly different from each other, as reflected in the global p-value for ART duration 
(p=0.005) (Table 2.2a). This attenuation of relative weight loss when individuals were on ART 
for two to five years, compared to 0 to <2 years, suggested a U-shaped association with long-
term use of ART and BMI: Once on ART for two or more years, individuals ‘caught up’ on 
weight gain with the HIV- reference population (See Figure S2.4 for plotted BMI and SBP 
trajectories in all subgroups). 
The IPW sensitivity analysis showed qualitatively similar, quantitatively attenuated, results 
(Table 2.2b) compared to the complete case analysis. We confirmed an increase in BMI in the 
HIV- group by 2010, but it was statistically non-significant according to the IPW model. BMI in 
the  HIV+ART0–<2yrs group dropped by –3.66 kg/m2 (95% CI –6.32 to –0.984; p=0.007) 
compared to the HIV- reference group. The relative drop in BMI of the HIV+ART2–5 yrs versus 
the HIV- group was not statistically significant, paralleling the findings of the complete case 
analysis. The drop in BMI was significantly greater among HIV+ART0-<2yrs versus HIV+ART2–
5yrs (p=0.032). 
Further sensitivity analyses (Table S2.2) including the full baseline population to calculate 
probability weights confirmed the robustness of the complete case results (Table S2.2b). 
Excluding individuals with BMI > 50kg/m2, the drop in BMI in the HIV+ART0–<2yrs group was 
further attenuated (–2.43 kg/m2 (95% CI –4.21 to –0.644; p=0.008)) (Table S22c). Notably, the 
change in BMI between 2003 and 2010 in the HIV- group was slightly higher at 1.03 kg/m2 (95% 
CI 0.614 to 1.45; p<0.001) compared to the analogous result of the complete case analysis. 
Overall, the findings of both sensitivity analyses were qualitatively in alignment with the results 
of the complete case analysis.  
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 Table 2.2ab: Effect of ART and HIV on longitudinal change of BMI. 2.2a: Population Average Model. BMI changed 
significantly between years 2003 and 2010 in the HIV-negative group and among ART users less than 2 years on ART. Data for 
people with unknown HIV status not shown. 2.2b: Population average model with IPW. The results presented in this table are 
based on a population average linear regression model using IPW adjusting for missingness due to loss to follow up, migration, 
and non-consent (but not death and severe illness). The weights were based on age, sex, education, general health, and an asset 
index indicator. The model controlled for age, sex, HIV, and ART status. 
2.2a: Population Average Model: Effect of ART and HIV on longitudinal change of BMI 
 BMI, 2003 (95% CI) 
BMI, 2010 
(95% CI) 
ΔBMI (03-10) 
(95%CI) 
p-value for 
1st diff  
DID effect 
(95%CI) 
p-value 
(DID) 
Global p-
value 
ART 
duration 
p-value 
HIV- 29.5 (28.7, 30.3) 
30.4 
(29.7, 31.1) 
0.874 
(0.339, 1.41) 0.001** (ref) 
<0.001** 
 Seroconverters 28.6 (26.3, 30.9) 
28.3 
(26.0, 30.7) 
-0.274 
(-1.95, 1.41) 0.749 
-1.15 
(-0.252, 2.83) 0.202 
HIV+ART- 27.6 (25.8, 29.4) 
27.4 
(25.6, 29.2) 
-0.196 
(-1.51, 1.12) 0.771 
-1.07 
(-2.50, 0.361) 0.173 
HIV+ART0–<2 yrs 30.2 (27.1, 33.3) 
25.9 
(22.8, 29.0) 
-4.34  
(-6.58, -2.10) <0.001** 
-5.21 
(-7.53, -2.89) 
<0.001*
* 
0.005** 
HIV+ART2–5 yrs 26.5 (24.5, 28.5) 
26.1 
(24.0, 28.0) 
-0.475  
(-1.91, 0.957) 0.515 
-1.35 
(-2.89, 0.189) 0.086 
2.2b: Effect of ART and HIV on longitudinal change of BMI (adjusted for loss to follow up) 
HIV- 29.8 (28.8, 30.9) 
30.4  
(29.4, 31.4) 
0.554 
(-.228, 1.34) 0.165 (ref) 0.0001**  
Seroconverters 29.0 (27.2, 30.7) 
28.8 
(27.1, 30.6) 
-0.128 
(-1.06, 0.806) 0.788 
-0.682 
(-1.90, 0.536) 0.273 
 
 
HIV+ART- 27.8  (26.3, 29.3) 
27.4 
(25.4, 29.4) 
 -0.404 
(1.48, 0.675) 0.463 
-0.958 
(-2.29, 0.375) 0.159 
HIV+ART0–<2 yrs 29.3 (26.0, 32.6) 
26.2 
(23.9, 28.5) 
-3.11 
(-5.66,-0.547) 0.017* 
-3.66 
(-6.32, -0.984) 0.007** 
0.032* 
 
HIV+ART2–5 yrs 26.8 (24.8, 28.7) 
26.7 
(25.1, 28.4) 
-0.012 
(-1.20, 1.18) 0.984 
 -0.566 
(-1.99, 0.860) 0.437 
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Further, with wide-scale ART starting in 2004, those starting in 2004/05 might have been more 
urgently in need than those starting on ART in 2006 and beyond. Consequently, the modifying 
effect of ART on BMI and BP might have been different in the ‘early starters’. We therefore 
conducted sensitivity analyses by excluding those on ART for four to five years (who initiated 
therapy between 2005 and 2007) for all models. None of the main results were changed with 
respect to the estimated effect size.  However, the power was negatively impacted due to sample 
size reduction (results not shown).   
Blood pressure change 2003 - 2010 
Between 2003 and 2010, modeled SBP based on the complete case analysis dropped from 130.4 
mmHg (95% CI 125.0 to 135.0) to 123.5 mmHg (95% CI 118.2 to 128.9) in the HIV+ART- 
group (pdifference= 0.010). In the weighted analysis, the drop in SBP in the HIV+ART2–5yrs group 
was also significant with a drop of –5.64mmHg (95% CI –11.2 to –0.07; p=0.047) (Table 2.3b).   
All other observed SBP changes between 2003 and 2010 were not statistically significant in both 
complete case and weighted analysis. The results for the modeled changes in SBP of the 
weighted analysis were qualitatively similar to that of the complete case analysis. 
We further investigated SBP changes relative to the HIV- comparison group. The relative change 
in SBP in the HIV+ART– group was significant with –7.55 mm Hg (95% CI –13.2 to –1.90; 
p=0.009) (Table 2.3a). This relative decline was greater in the weighted analysis, where the 
difference in SBP change between the HIV+ART– group and the control group was –9.09mm Hg 
(95% CI –14.6 to –3.61; p=0.001) (Table 2.3b). Overall, the relative change in SBP compared to 
	   71 
the HIV-negative reference group was not significantly different among all subgroups. The ART 
dose effect was also not statistically significant based on the complete case analysis. 
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Table 2.3ab: Effect of ART and HIV on longitudinal change of SBP. 2.3a: Population average model. SBP 
changed significantly between years 2003 and 2010 among ART users less than 2 years on ART. 2.3b: Population 
average model with IPW. The results presented in this table are based on a population average linear regression 
model using IPW adjusting for missingness due to loss to follow up, migration, and non-consent (but not death and 
severe illness). The weights were based on age, sex, education, general health, and an asset index indicator. The 
model controlled for age, sex, HIV, and ART status. 
2.3a: Effect of ART and HIV on longitudinal change of SBP 
 SBP 2003 (95% CI) 
SBP, 2010 
(95% CI) 
ΔSBP (03-10) 
(95%CI) 
p-value 
for first 
diff 
DID effect 
(95%CI) 
p-value 
(DID) 
Global 
p-value 
ART 
duration 
p-value 
HIV- 126.5 (124.3,128.3) 
127.0 
(124.8,129.1) 
0.427 
(-1.69, 2.54) 0.693 (ref) 
0.070 
 Seroconverters 123.6 (116.7,130.4) 
129.1 
(122.2,135.9) 
5.5 
(-1.17, 12.2) 0.106 
5.01 
(-1.94, 12.1) 0.156 
HIV+ART- 130.4 (125.0, 135.0) 
123.5 
(118.2, 128.9) 
-6.86 
(-12.1, -1.66) 0.010* 
-7.55 
(-13.2, -1.90) 0.009** 
HIV+ART0–<2 yrs 118.9 (109.9, 127.9) 
118.9 
(109.9,127.9) 
0.00 
(-8.76, 8.76) 1.00 
-0.36 
(-9.44, 8.72) 0.938 
0.853 
HIV+ART2–5 yrs 125.8 (120.0, 131.7) 
124.8 
(119.0, 130.7) 
-0.977 
(-6.64, 4.69) 0.735 
-1.35 
(-7.43, 4.73) 0.663 
2.3b: Effect of ART and HIV on longitudinal change of SBP (adjusted for loss to follow up) 
HIV- 127.1 (124.8,129.4) 
125.6 
(123.4,127.7) 
-1.53 
(-3.88, 0.816) 0.201 (ref) 0.394  
Seroconverters 124.2 (118.9,129.5) 
128.3 
(123.3,133.2) 
4.06 
(-1.32, 9.44) 0.139 
5.60 
(-.275,11.5) 0.062 
 
 
HIV+ART- 132.0 (125.5,138.5) 
121.4 
(115.7,127.1) 
-10.6 
(-15.6, 5.66) 
<0.001*
* 
-9.09 
(-14.6, -3.61) 0.001** 
HIV+ART0–<2 yrs 118.0 (111.0,124.9) 
116.3 
(109.7,123.0) 
-1.62 
(-9.00, 5.75) 0.666 
-.093 
(-7.82, 7.64) 0.981 
0.0016** 
HIV+ART2–5 yrs 128.2 (121.2,135.3) 
122.6 
(118.1,127.1) 
-5.64 
(-11.2, -0.070) 0.047* 
-4.11 
(-10.2, 1.93) 0.182 	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The results of several sensitivity analyses of the effect of HIV status on blood pressure change 
are presented in Tables S2.3 – S2.7. Adjusting for BMI at baseline, the results of the change in 
SBP were qualitatively similar to the complete case results, and quantitatively fell between the 
results of the complete case and the weighted analysis (Table S2.3). Conducting a weighted 
analysis including information of those who died in the censoring weights, the drop in SBP in the 
HIV+ART2–5 yrs group was significant, similar to the results in the weighted analysis that 
excluded the information of the dead and very sick for weight estimation (Table S2.4b). The 
results of the sensitivity analysis that included fewer covariates were qualitatively similar to the 
results of the IPW analysis without the dead and very sick (Table S2.4c). 
 
Overall, the effect of HIV status and ART on DBP differed from their observed effect on SBP: 
whereas there was a significant drop in SBP in the HIV+ART- group, DBP significantly increased 
in the HIV- and among seroconverters: both in the complete case and the IPW analysis (Table 
S25ab), DBP significantly increased by more than 4mm Hg in the HIV- group (p<0.001) 
between 2003 and 2010. Seroconverters showed an increase in DBP of >7 mm Hg (p=0.001). 
None of the other observed DBP changes were statistically significant. 
All DBP subgroup-specific relative changes compared to the HIV- comparison group were non-
significant based on the main model. When adjusting for BMI at baseline (Table S2.6), using 
IPWs that included information of the full baseline population, and using IPWs based on fewer 
predictors (Table S2.7ab), the results remained robust.  
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DISCUSSION 
 
 
This study represents a population-based, longitudinal analysis of the modifying effect of HIV 
and ART on body mass and blood pressure.	  Our study includes a HIV- reference group and spans 
periods before and after intensive ART rollout – two features thus far unique to chronic disease 
risk factor analyses in sub-Saharan (HIV) cohorts. Importantly, the HIV- reference group allowed 
for an adjustment for the secular trend in BMI and BP. Further, the first BMI and BP 
measurement occurred well before wasting may have occurred in HIV+ individuals28,29, as the 
minimum difference between the first survey measurement and ART onset was well over a year 
(Figures S2.2-S2.3). 
We present several novel findings. The HIV+ART0-<2yrs group experienced a very significant 
decline in BMI compared to the HIV- reference group. This relative decline was attenuated and 
no longer significant among those on ART between two and five years. Thus, our results suggest 
that ART allows individuals to recover toward a trend in weight gain experienced by the HIV- 
population, without however surpassing their baseline weight.  
This ‘trend toward normal weight’ has been postulated in previous studies.30 It parallels the 
finding that large scale long-term ART can lead to a return to pre-HIV workforce productivity31, 
but also allays concerns that ART might lead to net weight gain in the long-term. Nevertheless, 
the ‘trend toward normal’ in this study is a paradoxical benefit, as it represents a trend toward 
overweight and obesity. Food insecurity in rural KwaZulu-Natal remains a concern in the 
majority of the population, hence any programs to address the growing obesity rates will have to 
be sensitive to this underlying issue.  
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While the weight gain recovery on ART can be seen as a positive outcome – ART allows to a 
‘return to normal’ - our results warrant careful reflection. Health care providers need to 
judiciously consider when and for how long to counteract harmful weight loss in the early stages 
of ART regimen, and when to advise to slow weight gain in order to lessen CVD risk and other 
overweight and obesity-related complications. Our data provide first evidence that after two 
years on ART, there is no longer a significant difference in weight trajectory compared to the 
reference population. Thus, nutrition and exercise interventions to curb weight gain might be 
sensible starting then.  
As community health workers frequent HIV+ individuals, this offers an opportunity for greater 
sensitization of the HIV+ population toward the risks of obesity and hypertension. If staff 
training and resources permitted, excessive weight gain and high blood pressure could be 
monitored and managed concurrent with HIV surveillance and ART therapy.  
However, research on the effectiveness of infectious and chronic disease service integration is 
still ambivalent. It is not clear whether integration of infectious and chronic disease factor 
monitoring may weaken current HIV management efforts. In a systematic review on the impact 
of integrating primary healthcare services in LMICs at the point of delivery, Dudley & Garner 
examined the effect of integration on healthcare delivery, user views (satisfaction), and health 
status.32 While adding services (i.e. diabetes screening being added to HIV treatment and care) 
improved the use of the added-on service, there was very little evidence that health status was 
improved by service integration. In some cases, integration also led to deteriorating service 
delivery.32 Therefore, an important avenue of further study would be to assess the effectiveness 
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of chronic and infectious disease prevention efforts, and to arrive at best practice 
recommendations in emerging economies and low-income settings. 
An additional recommendation emerging from our study was to also monitor waist 
circumference and the waist-to-hip-ratio (WTHR). There exists ample evidence that waist 
circumference and WTHR are much greater predictors of mortality and disease risk than BMI.33-
36 Several previous studies have shown that weight gain during ART therapy favors abdominal 
versus limb fat accumulation, thereby exposing someone on ART with the same BMI as a HIV-
negative person to a higher CVD and mortality risk.30 Women are particularly affected with 
visceral adipose tissue accumulation as an effect of ART. Therefore, despite the fact that the 
herein presented study did not allow for examination of the change of WTHR between 2003 and 
2010 between the various HIV subgroups, it is highly likely that the ‘return to normal’ BMI in 
the long-term ART exposure group was characterized by an increase in VAT, and thereby, a 
relative increase in CVD risk compared to the HIV- population.  
For blood pressure changes, ART use (both short-term and long-term use) showed BP 
stabilization over seven years, similar to parallel HIV- individuals in same cohort; in contrast, 
HIV+ individuals with no ART use showed substantial drop in BP compared to ART users. Thus 
ART use yielded a positive blood pressure trajectory relative to HIV non-ART individuals. 
Notably, the HIV+ART- group had the highest average systolic blood pressure in 2003. This 
indicates a potentially unhealthier lifestyle in the HIV+ART- group compared to the HIV- group. 
Further, compared to the HIV- group, SBP in the HIV+ART– group showed a significant decline. 
We were unable to determine whether this overall drop in SBP from 130.4mmHg to 123.5 
mmHg was due to HIV-related side effects or due to improved clinical care (a SBP >130mmHg 
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is considered elevated blood pressure, is associated with a higher risk of cardiomyopathies, and a 
higher risk of recurrent strokes37).  Likely, the large drop in SBP in this population might be 
explained by additional blood pressure monitoring paralleling intensive health checks post HIV 
diagnosis. To test this hypothesis, detailed healthcare records, a larger sample size, and 
additional longitudinal data points would be necessary. 
LIMITATIONS 
There were several additional unknowns and potential time-variant confounders in our analysis, 
which we were unable to control for due to lack of data availability. The most important of these 
unmeasured potential confounders were detailed information on health status and the presence of 
other infections (particularly in HIV-positive patients), level of ART adherence, viral load 
information, drug resistance, and whether ART patients were on first or second line treatment 
regimen. Thus, our results are to be interpreted as population based associations, bearing in mind 
these potential confounders.  
Furthermore, our study would have benefitted from more measurement points both between 
2003 and 2010 and thereafter. This would allow to better evaluate the BMI trajectory differences 
in the various BMI subgroups and to draw stronger conclusions with regard to the ‘back to 
normal weight’ hypothesis. As only a subset of the demographically surveyed population in 2003 
and 2010 were assessed for body mass and blood pressure, our study and results might lack 
wider external validity. In addition, our study experienced a large loss to follow up, which we 
addressed by conducting IPW sensitivity analyses. Our results were qualitatively robust to these 
analyses sensitivity analyses. Nevertheless, further research with planned, intensive follow up is 
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needed.  This will help in planning to address to growing burden on non-communicable diseases 
in South Africa and surrounding nations. 
CONCLUSION 
Short-term ART (0–<2 years) was associated with a larger weight loss compared with no or 
long-term ART. Once on ART for two or more years, individuals ‘caught up’ on weight gain 
with the HIV- reference population. Such a longitudinal finding of parallel trajectories of short-
/long-term ART users and HIV+ and HIV- populations have, to our knowledge, never been 
reported before. Our results thus showcase the importance of health system readiness to address 
the burgeoning double burden of disease in Sub-Saharan Africa. As emerging economies face the 
double burden of non-communicable and infectious diseases, further research based on cohort 
studies with both HIV-positive and HIV-negative populations will be needed to shine light into 
the trends and treatment opportunities of chronic disease (risk factors) in these populations. 
 
 
 
RESEARCH IN CONTEXT 
 
We searched PubMed with the terms “HIV”, “ART”, “Africa”, and (“Cardiovascular” or “BMI” or 
“Blood pressure” or “Weight” not “Pregnancy”), for articles published between Jan 1, 2000, and 
November 25, 2014. We restricted our search to articles available in English. We identified a 
comprehensive systematic review that included all articles identified through our original search up to 
January 1, 2012. We then restricted our search to articles published between Jan 1, 2012, and 
November 25, 2014. Among the 109 identified studies, 106 studies were excluded based on title, 
abstract, and data review. 
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The 2013 meta-analysis concluded that HIV infection was associated with both lower systolic and 
diastolic blood pressure, but evidence on the effect of ART on blood pressure was weak or non-
existent.14 Dillon et al emphasized the need for further research in this area to more reliably manage 
chronic disease risk in HIV-infected populations in SSA. 
The additional three studies revealed during our review showed that pre-ART weight was a predictor of 
onset of diabetes on ART15, that ART was associated with non-HIV related, chronic morbidity16, and 
that ART was associated with increased central fat (a cardio-metabolic disease marker) and reduced 
peripheral fat.17 We did not identify studies that were longitudinal studies including both a HIV- control 
group and that spanned both periods before and after ART rollout. 
 
INTERPRETATION 
 
Based on our findings, short-term ART (0 to <2 years) is associated with a larger weight loss compared 
with no or long-term ART. This attenuation of relative weight loss when individuals were on ART for 
two to five years, compared to 0 to <2 years, suggests a U-shaped association with long-term use of 
ART and BMI: Once on ART for two or more years, individuals ‘catch up’ on weight gain with the 
HIV- reference population. Our study revealed the need for additional evidence of the effect of HIV 
and ART on cardiovascular and chronic disease risk, particularly in high-prevalence, low-income 
populations. In addition, further evidence on optimal health systems solutions to address the double 
burden of chronic and infectious disease is needed. 
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SUPPLEMENTARY APPENDIX 2 
 
THE EFFECT OF HIV AND THE MODIFYING EFFECT OF ANTI-RETROVIRAL THERAPY (ART) ON 
BODY MASS INDEX (BMI) AND BLOOD PRESSURE LEVELS IN RURAL SOUTH AFRICA 
Andrea B Feigl, David E Bloom, Goodarz Danaei, Deenan Pillay, Joshua A Salomon, Frank 
Tanser, Till W Bärnighausen 
 
 
SUPPLEMENTAL TABLES  
 
 
Table S2.1: Additional baseline characteristics of the complete case study population in 2003 
(n=505), including p-values. This table shows the unadjusted sex, age, weight, height, BMI, SBP, 
DBP, and HIV status characteristics of the study population. Age, weight, and BMI differed 
significantly among the subgroups at baseline.  
Characteristics 
mean (SD) 
Overall 
sample 
population 
(n=505) 
HIV- 
(n=347) 
HIV+ART- 
(n=52) 
HIV+ART+ 
(n=62) 
Refused 
Testing 
(n=44) 
p-value 
Sex (female, %) 81.78 % 81.27% 80.77% 77.42% 93.18% 0.23 
Years of age (SD) 39.5 (7.2) 40.2 (7.2) 37.3 (7.1) 37.6 (7.8) 38.8 (5.5) 0.005** 
Weight, kgs (SD) 74.9 (18.8) 76.1 (19.1) 69.1 (15.6) 71.2 (19.1) 77.44 (17.3) 0.024* 
Height, cms (SD) 160.8 (7.3) 160.9 (7.3) 159.1 (9.1) 162.0 (6.9) 160.7 (5.9) 0.226 
BMI (SD) 29.0 (7.2) 29.5 (7.4) 27.4 (6.0) 27.2 (7.1) 30.1 (7.0) 0.029* 
Years on ART 
(SD)    2.5 (1.4)   
% on ART for 0-
1.9 years    29.03%   
CD4+ count at 
ART initiation    136.5 (78.7)   
SBP, n=502, (SD) 126.7 (20.2) 127.1 (20.7) 129.3 (22.2) 122.3 (17.4) 125.6 (17.8) 0.270 
DBP, n=502, (SD) 80.6 (13.2) 80.9 (13.5) 81.0 (14.0) 78.0 (10.7) 81.0 (12.5) 0.436 
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Table S2.2: Effect of ART and HIV on longitudinal change of BMI – robustness checks. S2.2a: The results 
presented in this table are based on a population average linear regression model using IPW adjusting for 
missingness due to loss to follow up, migration, and non-consent (but not death and severe illness). The weights 
were based on age, sex, education, general health, and an asset index indicator. The model controlled for age, sex, 
HIV, and ART status. S2.2b: Same as S2.2a, but weights included information at baseline of those who 
subsequently die or fell ill. S2.2c: The results presented in this table are based on a population average model 
(without IPW), but excluded all outliers with BMI<50kg/m2 at baseline and follow-up. 
 S2.2a: IPW (without dead and very sick) 
S2.2b: IPW with all lost to follow-
up 
S2.2c: BMI < 50kg/m2, general 
model 
 ΔBMI (03-10) (95%CI) p-value 
ΔBMI (03-10) 
(95%CI) p-value 
ΔBMI (03-10) 
(95%CI) p-value 
HIV- 0.554 (-0.228, 1.34) 0.165 
0.747 
(0.048, 1.45) 0.036* 
1.03 
(0.614, 1.45) <0.001** 
Seroconverters -0.128 (-1.06, 0.806) 0.788 
-0.047 
(-0.956, 0.862) 0.920 
-0.128 
(-1.06, 0.806) 0.788 
HIV+ART- -0.404 (1.48, 0.675) 0.463 
-0.294 
(-1.45, 0.866) 0.619 
-0.786 
(-1.83, 0.254) 
0.138 
 
HIV+ART0–<2 
yrs 
-3.11 
(-5.66, -0.547) 0.017* 
-3.99 
(-7.82, -0.164) 0.041* 
-2.43 
(-4.21, -0.644) 
0.008** 
 
HIV+ART2–5 
yrs 
-0.012 
(-1.20, 1.18) 0.984 
-0.270 
(-1.10, 0.565) 0.527 
-0.475 
(-1.58, 0.633) 
0.400 
 
 
 
Table S2.3: Effect of ART and HIV on longitudinal change of SBP. SBP changed 
significantly between years 2003 and 2010 among ART users less than 2 years on ART. 
Adjusted for BMI at baseline. 
Population average model – adjusted for BMI at baseline 
HIV Group SBP 2003 (95% CI) 
SBP, 2010 (95% 
CI) 
ΔSBP (03-10) 
(95%CI) 
p-value for 
first 
difference est. 
HIV- 126.6 (124.4,128.8) 
126.9 
(124.7,129.2) 
0.368 
(-1.75, 2.48) 0.734 
Seroconverters 123.418 (116.6,130.2)  
128.82 
(122.1,135.5) 
1.67 
(-3.94, 7.28) 0.560 
HIV+ART- 131.6 (126.4,136.8) 
124.4 
(119.2,129.62) 
-7.23 
(-12.4, 2.03) 0.006** 
HIV+ART0–<2 yrs 118.3 (109.8,126.9) 
118.3 
(109.8,126.9) 
0.00 
(-8.77, 8.77) 1.00 
HIV+ART2–5 yrs 127.226 (121.8, 132.6) 
126.241 
(120.9,131.6) 
-0.984 
(-6.64, 4.67) 0.733 
 
  
	  	   89 
Table S2.4: Effect of ART and HIV on longitudinal change of SBP – robustness checks. S2.4a: The 
results presented in this table are based on a population average linear regression model using IPW adjusting 
for missingness due to loss to follow up, migration, and non-consent (but not death and severe illness). The 
weights were based on age, sex, education, general health, and an asset index indicator. The model controlled 
for age, sex, HIV, and ART status. S2.4b: Same as S2.4a, but weights included information at baseline of 
those who subsequently die or fell ill. S2.4c: (population average model) with IPW (fewer covariates). The 
results presented in this table are based on a population average linear regression model using IPW adjusting 
for missingness due to loss to follow up, migration, and non-consent. The weights were based on age, sex, 
and education. The model controlled for age, sex, HIV, and ART status. 
 S2.4a: IPW (without dead and very sick) 
S2.4b: IPW with all lost to 
follow-up 
S2.4c: IPW without dead 
and very sick, fewer 
covariates 
 ΔSBP (03-10) (95%CI) p-value 
ΔSBP (03-10) 
(95%CI) p-value 
ΔSBP (03-10) 
(95%CI) p-value 
HIV- -1.53 (-3.88, 0.816) 0.201 
-1.72 
(-4.10, 0.661) 0.157 
-1.12 
(-3.39, 1.14) 0.330 
Seroconverters 4.06 (-1.32, 9.44) 0.139 
4.13 
(-1.22, 9.48) 0.130 
4.04 
(-0.938, 9.75) 0.106 
HIV+ART- -10.6 (-15.6, 5.66) <0.001** 
-11.4 
(-16.5, -6.17) <0.001** 
-9.81 
(-14.7, -4.90) <0.001** 
HIV+ART0–<2 
yrs 
-1.62 
(-9.00, 5.75) 0.666 
-1.98 
(-10.7, 6.79) 0.659 
-.595 
(-7.74, 6.55) 0.870 
HIV+ART2–5 
yrs 
-5.64 
(-11.2, -0.070) 0.047* 
-6.04 
(-11.7, -0.387) 0.036* 
-4.84  
(-10.3, 0.628) 0.083 
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Table S2.5ab: Effect of ART and HIV on longitudinal change of DBP. S2.5a: Population average model. 
DBP changed significantly between years 2003 and 2010 among ART users less than 2 years on ART. S2.5b: 
Population average model with IPW. The results presented in this table are based on a population average linear 
regression model using IPW adjusting for missingness due to loss to follow up, migration, and non-consent (but 
not death and severe illness). The weights were based on age, sex, education, general health, and an asset index 
indicator. The model controlled for age, sex, HIV, and ART status. 
S2.5a: Effect of ART and HIV on longitudinal change of DBP 
 DBP 2003 (95% CI) 
DBP, 2010 
(95% CI) 
ΔDBP (03-
10) (95%CI) 
p-value 
for first 
diff 
DID effect 
(95%CI) 
p-value 
(DID) 
Global 
p-value 
ART 
duration 
p-value 
HIV- 80.6 (79.2, 82.0) 
85.4 
(84.0, 86.9) 
4.85 
(3.42, 6.28) <0.001** (ref) 
0.735 
 Seroconverters    78.9 (74.5, 83.4) 
86.9 
(82.5, 91.4) 
8.00 
(3.48, 12.5) 0.001** 
3.15 
(-1.59, 7.89) 0.192 
HIV+ART-   81.5 (78.0, 85.0) 
84.7 
(81.2, 88.2) 
3.15 
(-.374, 6.67) 0.080 
-1.70 
(-5.50, 2.10) 0.380 
HIV+ART0–<2 yrs 77.0 (71.1, 82.8) 
   80.0 
(74.2, 85.9) 
3.06 
(-2.87, 8.98) 0.312 
-1.79 
 (-7.89, 4.30) 0.564 
0.0683 
HIV+ART2–5 yrs   79.7 (76.0, 83.5) 
  79.7 
(77.8, 85.4) 
1.84  
(-2.00, 5.67) 0.348 
-3.01 
(-7.11, 1.08) 0.149 
S2.5b: Effect of ART and HIV on longitudinal change of DBP (adjusted for loss to follow up) 
HIV- 80.8 (79.2, 82.5) 
  85.0 
(83.6, 86.4) 
4.19 
(2.57, 5.82) <0.001** (ref) 
0.284    
 Seroconverters 78.5 (74.6, 82. 3) 
86.2 
(81.7, 90.7) 
7.76 
(3.18, 12.3) 0.001** 
3.56 
 (-1.29, 8.43) 0.150 
HIV+ART- 81.5 (76.6, 86.4) 
  83.9 
(80.0, 87.8) 
2.36 
 (-0.882, 
5.61) 
0.153 -1.83  (-5.46, 1.80) 0.324 
HIV+ART0–<2 yrs   76.03 (71.0, 81.0) 
78.8 
(74.4, 83.3) 
2.79 
 (-2.22, 7.80) 0.275 
-1.40 
 (-6.67, 3.86) 0.602 
0.0092** 
HIV+ART2–5 yrs 80.8 (77.2, 84.3) 
80.1 
(77.1, 83.0) 
-0.691 
 (-4.62, 3.24)   0.730 
-4.88 
 (-9.13, -
0.631) 
0.024* 
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Table S2.6: Effect of ART and HIV on longitudinal change of DBP (population average 
model). SBP changed significantly between years 2003 and 2010 among ART users less than 2 
years on ART. Adjusted for BMI at baseline. 
Population average model – adjusted for BMI at baseline 
HIV Group DBP 2003 (95% CI) 
DBP, 2010 (95% 
CI) 
ΔDBP (03-10) 
(95%CI) 
p-value for 
first 
difference est. 
HIV- 80.6 (79.2, 82.0) 
85.4 
(84.0,86.8) 
4.79  
(3.36, 6.22)   <0.001** 
Seroconverters 78.7 (74.4, 83.0) 
86.6 
(82.4, 90.8) 
7.86  
(3.35,12.4) 0.001** 
HIV+ART-   82.5 (79.3, 85.7) 
85.3 
(82.1, 88.6) 
2.85 
(-.670, 6.36) 0.113 
HIV+ART0–<2 yrs    76.7  (71.4, 82.0) 
79.8 
(74.5, 85.1) 
3.06 
(-2.88, 8.99) 0.313 
HIV+ART2–5 yrs 80.8 (77.3, 84.3) 
82.6 
(79.2, 86.1) 
1.82 
 (-2.00, 5.65)   0.350 
 
 
Table S2.7: Effect of ART and HIV on longitudinal change of DBP – robustness checks. S2.7a: The results 
presented in this table are based on a population average linear regression model using IPW adjusting for 
missingness due to loss to follow up, migration, and non-consent (but not death and severe illness). The weights 
were based on age, sex, education, general health, and an asset index indicator. The model controlled for age, sex, 
HIV, and ART status. S2.7b: Same as S2.7a, but weights included information at baseline of those who 
subsequently die or fell ill. S2.7c: (population average model) with IPW (fewer covariates). The results presented in 
this table are based on a population average linear regression model using IPW adjusting for missingness due to loss 
to follow up, migration, and non-consent. The weights were based on age, sex, and education. The model controlled 
for age, sex, HIV, and ART status. 
 S2.7a: IPW (without dead and very sick) 
S2.7b: IPW with all lost to follow-
up 
S2.7c: IPW without dead and 
very sick, fewer covariates 
 ΔDBP (03-10) (95%CI) p-value 
ΔDBP (03-10) 
(95%CI) p-value 
ΔDBP (03-10) 
(95%CI) p-value 
HIV- 4.19 (2.57, 5.82) <0.001** 
4.13 
(2.51, 5.74) <0.001** 
4.57 
 (2.99, 6.16) <0.001** 
Seroconverters 7.76 (3.18,12.3) 0.001** 
7.81 
(3.04, 12.6) 0.001** 
7.93 
(3.76, 12.1)  <0.001** 
HIV+ART- 2.36  (-0.882, 5.61) 0.153 
2.01 
(-1.40, 5.41) 0.248 
2.05 
 (-1.41, 5.51) 0.245 
HIV+ART0–<2 
yrs 
2.79 
 (-2.22, 7.80) 0.275 
2.91 
(-2.07, 7.89) 0.252 
3.01 
 (-1.40, 7.42) 0.181 
HIV+ART2–5 
yrs 
-.691 
 (-4.62, 3.24)   0.730 
-.993 
(-4.91, 2.92) 0.619 
0.314 
(-3.60, 4.23) 0.875 
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Table S2.8: Estimation and characteristics of the IPWs  
 
 Estimated Inverse Probability Weights 
Weight Specification Mean (SD) Min/ Max 
1. Probability of participation predicted based on geographic 
sampling block, HIV status (at baseline), age, sex, self 
reported health status (at baseline), highest education attained 
(at baseline), and asset index (at baseline); missing variables 
were coded via missing indicators; those lost to follow up due 
to death or severe illness were not included  
0.999 (0.674) 0.357  / 5.92 
2. Probability of participation predicted based on geographic 
sampling block, HIV status (at baseline), age, sex, self 
reported health status (at baseline); missing variables were 
coded via missing indicators; those lost to follow up due to 
death or severe illness were not included  
1.01 (0.532) 0.364  / 3.85 
As in 1., and those lost to follow up due to death or severe 
illness were included  1.01 (0.738) 0.314  / 7.29 
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SUPPLEMENTAL FIGURES 
 
	  
Figure S2.1: Years between first weight measurement and ART Initiation, All ART groups 
 
	  
Figure S2.2: Years between first weight measurement and ART Initiation, long-term ART group 
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Figure S2.3: Years between first weight measurement and ART Initiation, short-term ART group 
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Figure S2.4: BMI and SBP Changes, 2003-2010 
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LITERATURE REVIEW 
 
We searched PubMed with the terms “HIV”, “ART”, “Africa”, and (“Cardiovascular” or “BMI” 
or “Blood pressure” or “Weight” not “Pregnancy”), for articles published between Jan 1, 2000, 
and November 25, 2014. We restricted our search to articles available in English. We identified a 
comprehensive systematic review that included all articles identified through our original search 
up to January 1, 2012. We then restricted our search to articles published between Jan 1, 2012, 
and November 25, 2014. Among the 109 identified studies, 106 studies were excluded based on 
title, abstract, and data review. 
The 2013 meta-analysis concluded that HIV infection was associated with both lower systolic 
and diastolic blood pressure, but evidence on the effect of ART on blood pressure was weak or 
non-existent.1 Dillon et al emphasized the need for further research in this area to more reliably 
manage chronic disease risk in HIV-infected populations in SSA. 
The additional three studies revealed during our review showed that pre-ART weight was a 
predictor of onset of diabetes on ART2, that ART was associated with non-HIV related, chronic 
morbidity3, and that ART was associated with increased central fat (a cardio-metabolic disease 
marker) and reduced peripheral fat.4 We did not identify studies that were longitudinal studies 
including both a HIV- control group and that spanned both periods before and after ART rollout. 	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PAPER #3: MICROCLINIC SOCIAL NETWORK INTERVENTIONS FOR OBESITY 
AND DIABETES IN AMMAN, JORDAN: A 6-MONTH, 3-ARMED CLUSTER 
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ABSTRACT  
 
 
Background In Jordan, close to 20% of adults are diabetic, and over 75% are overweight/obese. 
Diabetes (DM) preventive interventions are lacking and costly. 
 
Objective To address this health burden, we evaluated the effect of leveraging current social 
networks of friends and family using the Microclinic Social Network (MSN) program via a 
multi-center, 28 week, 3-arm, cluster-randomized clinical trial in Jordan. 
 
Design, Setting, and Participants Participants were diabetic or pre-diabetic, or had >=1 risk 
factor and family history of DM. Between 2011 and 2013, 920 participants were enrolled at four 
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centers and randomized at the group level to either (A) enhanced MSN program with interactive 
sessions; (B) basic MSN diabetes health education; or (C) standard monitoring and care. 
 
Main Outcome and Measures Primary outcomes were cross-arm difference-in-differences 
(DID) in weight, BMI, and HbA1c at 14 weeks, 28 weeks, and 12 month follow-up. DID in waist 
circumference, blood pressure, and fasting plasma glucose were also collected. Inverse 
probability weighting was used to address missingness. 
 
Results Participants were 66% women, with mean (SD) age 55.1 years (10.2) and mean 
BMI=33.6 (3.2). After 14 weeks, the DID in weight change of Arm A (n=545) vs control 
(n=188) was -0.6 kg (95%CI: -1.1 to -0.1), and -0.2kg (-0.5 to 0.01) in Arm B (n=187) versus 
control. At 28 weeks, the DID of weight change of Arm A vs C -1.2 kg (-1.7 to -0.5), while the 
DID of Arm B vs Arm C was not significant. Analyses correcting for dropouts yielded 
significant results for weight -0.9kg (-1.8 to -0.1) and HbA1c -0.2% (-0.4 to -0.1) for A vs C at 28 
weeks. At 12 months, DID in weight and HbA1c were not different across groups. However, loss-
to-follow-up was 50%, and thus the 12-month results to-date are inconclusive. Further follow-
ups are planned at 16- and 30-months. 
 
Conclusions Overall, the enhanced MSN intervention was effective in significantly reducing 
weight over a 28 week intervention period; HbA1c results also suggested modest improvements. 
Further studies that leverage social networks are needed. 
 
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01596244  
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INTRODUCTION 
 
Non-communicable diseases (NCDs) comprise an increasingly large percentage of the overall 
disease burden in the Middle East.1,2 In Jordan, NCDs were responsible for more than 50% of all 
deaths in 2005, and this fraction has increased since then.3 Ischemic heart disease, congenital 
anomalies, and stroke were estimated to be the top three reasons for premature death in Jordan in 
2013, with diabetes ranking at number five.4-6 High body-mass index (BMI), dietary risks, high 
fasting plasma glucose (FPG), high blood pressure (BP), smoking, and physical inactivity 
contributed over 45% of all disability-adjusted life years lost (DALYs) in Jordan in 2010.7 
 
Despite the large disease and economic burden of chronic diseases8, national strategies to address 
NCDs in Jordan specifically, and the Middle East overall, have been lacking.1,9 Ajlouni et al 
showed that 54% of diabetics in Jordan received insufficient care, and that women are 
disproportionately affected by the obesity epidemic in Jordan.3 Chronic disease risk factor self-
management in Jordan remains poor, and wanes with increasing time post-diagnosis.3,10,11 
Therefore, cost-effective community prevention programs are necessary to change the tide of 
chronic disease risk factors. 
 
To achieve reliable and sustained control of chronic disease risk factors, long-lasting, low-cost 
self-management strategies, such as social-network focused interventions, are needed. Previous 
studies have established a strong effect of social networks on propagating behavior change 
related to chronic disease risk factors.12,13 However, these have been based on passive 
observational designs, which do not allow differentiation between social network modalities.14 
	  	   101 
Since 2005, Microclinic International (MCI) has pioneered the research and development of a 
novel social network ‘microclinic’ model to study if and how specifically social networks can be 
leveraged for diabetes and weight management.15-17 After a successful Microclinic trial in 
Kentucky, demonstrating sustained weight loss and improvements in blood glucose and 
cholesterol past the nine months of the intervention, MCI was invited to conduct a similar study 
in Jordan, to assess the potential success and transferability of this program to a low-resource 
setting. 
 
We thus conducted a randomized control study specifically designed to test the effectiveness of 
the 6-month Microclinic program in influencing lifestyle behavioral risk factors to improve 
diabetes management that effect weight and metabolic outcomes through social networks in 
Amman, Jordan. MCI conducted trial NCT01596244 in close collaboration with Queen Rania’s 
Royal Health Awareness Society and the Jordanian Ministry of Health. 
 
METHODS 
 
Trial Design and Setting 
The MCI trial was a multicenter, three-arm, cluster-randomized controlled trial that enrolled 
participants from four community health centers in Amman, Jordan. The study protocol was 
approved by institutional review boards in both the United States (Western Institutional Review 
Board) and locally (The National Center for Diabetes, Endocrinology, and Genetics, Amman 
Jordan). All participants provided written informed consent. The trial was rolled out in five 
waves (cycles) in four participating centers, with gaps of 15 -28 weeks between cycles. (See 
Appendix for detailed timeline). 
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Participants  
Recruitment through the local Ministry of Health (MoH) care centers utilized a combination of 
community outreach campaigns and patient recruitment within community health care centers. 
Active recruitment of the five cohort waves occurred during October 2011 – May 2013. The first 
intervention cohort started in January 2012.  
Community members were invited to a presentation at the local medical center to learn about the 
government-sponsored program.  At this meeting, potential participants were encouraged to 
bring friends and family members who met program eligibility criteria. All those interested in the 
program were eligible to register as a ‘microclinic cluster’. Before registering, any questions 
about the program were explained and participants signed a consent form to allow periodic data 
collection of behavioral and metabolic risk factors for program evaluation purposes. Men and 
women 18 years or older were eligible to participate in the study if they had been previously 
diagnosed with diabetes, were diagnosed with diabetes or pre-diabetes during recruitment, or 
were at risk of diabetes. Diabetes and pre-diabetes were confirmed by means of a fasting plasma 
glucose (FPG) test at recruitment, using criteria of 100-125 mg/dL for pre-diabetes, and 126 
mg/dL or higher for diabetes. Risk of diabetes was defined as having a history of diabetes in 
close family AND being overweight/obese, or as having a family history of diabetes AND 
having either high BP or high serum cholesterol. Pregnant and/or severely ill participants were 
not eligible to participate in the study. All participants needed to be able to understand, read, and 
sign the written consent form. 
 
Data Collection 
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Three types of data were collected as part of this randomized trial: clinical measures (height, 
weight, waist circumference, blood pressure, HbA1c, and fasting blood glucose), survey data 
(including knowledge about diabetes and obesity, healthcare access, exercise and dietary habits, 
education status, etc); and social network information (measuring how study participants were 
related and interacted with others within their social cluster and between others in their 
classroom group). The clinical data was collected by trained nurses and trained personnel at the 
MoH community health centers. The survey and social network data were collected via paper-
based surveys, and proctored by nurses and study coordinators. The timeline for the 
measurements throughout the six-month (28-week) intervention period and follow-up period are 
described in Table S3.1.  
 
Study Procedures  
Recruitment occurred in three phases. In phase 1, potential participants were encouraged to 
participate via posters in the five MOH clinics, via direct contact by study nurses/clinic staff 
based on medical record review, during patient clinic visits (nurses/ doctors discussed study with 
prospective participants), and by recruiting participants who had formerly participated in a prior 
longitudinal, non-randomized social network program.17 Upon declaration of willingness to 
participate, nurses invited prospective participants to an upcoming recruitment event on a 
specific day and at one of the five study centers (phase 2). Participants were required to fast eight 
hours before their appointment time. During phase 3, the recruitment event, eligibility criteria 
were verified, fasting blood glucose was measured, and a short lecture was given that described 
the purpose of the program and the associated study. To fulfill the social network component of 
the study, participants were encouraged to bring family members and close friends who might 
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also be eligible. After registering with the nurses as a social cluster, with one primary member of 
each cluster was designated as a ‘node’; the eligibility of all cluster members was verified. All 
eligible individuals were randomized in a cluster-based randomization procedure, where each 
node plus cluster was randomized to one of the three treatment arms. Randomization was 
stratified by study center (five total), and study waves (four total), resulting in a total of nine 
study cohorts. 
 
Biometric and Laboratory Measures 
Height was measured using a hospital & homecare scale with height meter; weight was measured 
using Health Scale SVR 160. Fasting Plasma glucose was measured via the finger prick method, 
using AccuCheck Performa. Digital readings on this device converted blood glucose 
concentrations to plasma glucose concentrations, conforming to international reporting 
standards. Omron and A&D blood pressure cuffs were used to measure blood pressure; both 
types measured SBP and DBP three consecutive times. HbA1c levels were tested at the Jordanian 
MoH Lab Centers via High Performance Liquid Chromatography (HPLC). 
 
Study Intervention 
The intervention was delivered over a timeframe of six months (28 weeks), and involved 14 
program sessions (Arm A and B), or 14 check-in appointments (Arm C). Both the detailed 
curriculum and the treatment schedule (including timeline for biometric, survey, and social 
network measurements) are shown in Appendix 1 (Table S3.1 and S7). 
Arm A received a full social-network based intervention, where participants in each classroom 
were encouraged and tasked to work within their assigned microclinic (MC) groups. These MCs 
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consisted of groups of two to six participants from pre-existing social networks (friends, 
relatives, coworkers, neighbors, etc)—with shared access to diabetes education, technology (via 
glucose meters), and group support to promote weight and metabolic control through diet, 
exercise, medication adherence, and blood pressure management. MC members played a role in 
the collective effort to combat diabetes and solidifying self-management behavioral skills 
through peer monitoring and encouragement of lifestyle behaviors. The detailed curriculum is 
shown in Appendix A, and included cooking and physical activity lessons, encouragement to 
work with assigned social networks (Arm A), a field visit to the gym, and several other 
behavioral and lifestyle intervention lessons. 
Intervention Arm B received an individually-focused educational intervention, with lessons on 
weight and metabolic control through diet, exercise, medication adherence, and blood pressure 
management, but without fostering and levering the social network component of the full MSN 
intervention. Control Arm C also attended the clinics at the same time intervals and frequency 
throughout the six-month study period; however, only measurements were taken, and no lessons 
were delivered to participants in this control arm. Additional follow-up visits were conducted 6-
months after the last intervention, and continuing data collection planned for 10-months, 14-
months, and 18-months post-intervention.  
 
Outcome Assessment 
Per study protocol, the primary outcome variables of this trial were 1) change in weight (i.e. 
BMI) from baseline to 3 and 6 months, 2) change in HbA1c (glycated hemoglobin) levels from 
baseline to 3 and 6 months. The secondary outcome variables were a) change in blood pressure 
from baseline to 3- and 6-months, b) change in waist circumference from baseline to 3 and 6 
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months, and c) change in FPG from baseline to 3- and 6-months. All primary and secondary 
outcome data were collected at the additional follow-up 12-months post-baseline measurement. 
 
Adverse Events and Safety monitoring  
The MOH nurses conducted safety monitoring throughout the trial and referred participants to 
clinicians if deemed necessary and rescue therapy was required. 
 
Masking  
Laboratory analysis for HbA1c was masked, as lab workers were not made aware which 
treatment group the samples came from. No masking took place for other measurements. 
 
Statistical Analyses  
We estimated the required sample size for Arm A vs C and B vs C (SD, 1%) assuming a 0.6% or 
greater reduction in HbA1c in Arm A vs C and B vs C over a 6-month intervention period.18,19 
Using a 2-tailed, 2-sample t test and .05 type I error, a sample size of 234 participants per group 
was required to achieve 90% power. In order to increase power and factor in potential attrition, 
the intended sample size was set at 300 per arm. Due to recruitment procedure modifications, the 
sample sizes at baseline were n= 545, 187, and 188 in arms A, B, and C, respectively.  
The trial data was structured as a longitudinal, multi-level, panel dataset. Individuals were nested 
within microclinic clusters, which in turn were structurally nested within classrooms, days, and 
cohorts (of different neighborhoods and temporal waves). In order to take account the multi-level 
data structure, we utilized multi-level, mixed effects models (random intercepts, random slopes). 
A particular advantage of multi-level models, which use partial pooling, is that they correct for 
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multiple testing, particularly when close biological correlation of outcome data is present.20 
Another advantage of multi-level models is that they additionally adjust for cluster 
randomization by allowing for within cluster-correlation. Conventional methods to adjust for 
cluster randomization, such as permutation tests or the Tukey-Kramer method, cannot commonly 
be combined with multi-level models, as the hierarchical structure accounts for within-cluster 
correlation.21 Further, for correcting potential regression to the mean, the residual change method 
as used, following the steps outlined by Blomquist.22,23  
Primary and secondary clinical outcomes were analyzed using the intention-to-treat principle, 
using the complete-case method. At each follow-up and measurement point, there was some 
missingness/loss to follow up (Table S3.3). As missingness might have been non-random and 
correlated with covariates and observed outcome, we applied inverse probability-of-censoring 
weights to remove selection bias.24 Baseline covariates, time-varying updated information, and 
change in primary outcome measure (HbA1c and weight change from baseline) up to the last 
measurement prior to the missingness/loss to follow up were used to compute stabilized inverse 
probability-of-censoring weights (IPCWs).25 The IPCW method assigns a weight to each non-
censored individuals and allows them to ‘represent’ those who have been lost to follow-up after 
adjusting for observed patient characteristics.24,26,27 Different covariates were used to calculate 
the censoring weights for missed measurements at 3-, 6-, and 12-months post baseline. The 
covariates for the equation estimating the weights, as well as the summary statists of the 
stabilized censoring weights are shown in Table S3.5. As age differed slightly among subgroups 
at baseline, all analyses are adjusted for age to account for residual effects of the age on the 
studied outcomes. All statistical analyses were performed using STATA 13.1. 
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RESULTS 
 
Participants at Baseline 
During the first recruitment phase, 1032 volunteers were screened for eligibility. Of these, 79 did 
not provide consent, and 33 did not meet the inclusion criteria (5 were pregnant, and 28 were 
neither diabetic or pre-diabetic) (Figure 3.1). Thus, 920 eligible individuals, who had presented 
themselves within 778 pre-existing social nodes (mode =1, cluster size range: 1-4), were 
randomized to the three treatment arms, in which 468 nodes (n=545) were randomly assigned to 
Arm A; 153 nodes (n=187) were randomized to Arm B; 157 nodes (n=188) were assigned to 
Arm C. The group intervention meetings for Arm A were held on Mondays, Tuesdays, and 
Wednesdays. Those for Arm B were held on Thursdays and Fridays. Participants of Arm C were 
able to choose a preferred day of the week to participate in the measurements. As the intended 
cluster size for the social network intervention in treatment Arm A was n=2 to 6, participants 
who had been randomized as individuals were asked to form groups of at least size 2-3 with 
relatives or friends also in the same class. This resulted in the formation of a total of 218 
microclinics (MCs) (n=545 individuals), with group sizes ranging from 2-5 participants per MC 
in Arm A. These MCs formed the basis of the social network focused curriculum in treatment 
Arm A. Of the 545 participants of Arm A, 403 completed the measurement at 6-months; 285 
completed the follow-up measurement at 12-month post baseline. In Arm B, 140/187 completed 
the 6-month measurements, and 109/187 completed the 12-month measurement. Similarly, in 
Arm C, 122/188 completed the measurements at 6 months, and 109/188 were present at the 12-
month follow-up (Table S3.1).  
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Figure 3.1: Study Flowchart, showing randomization and participation after 6-months 
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The baseline characteristics among the three treatment Arms were generally similar (Table 3.1), 
with minor exception of mean age in Arm A (mean = 54.1 years) vs Arm B (56.6 yrs) and Arm C 
(56.2 yrs). Overall, all study groups were comprised of >65% women, and >83% married 
participants. Prior diabetes education was extremely low (<3%), and mean BMI was > 33.4 
kg/m2 in all groups. Mean SBP was slightly lower in A (129.01mmHG) versus B and C (both > 
131.7 mmHg). Mean FPG ranged from 142.78 mg/dL in Arm B to 148.07 mg/dL in Arm C. 
Following the CONSORT guidelines, we did not report on the p-values of the difference in 
baseline characteristics, based on the reasoning that any significant differences would have 
arisen through a random process.28  
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Table 3.1. Baseline Participant Characteristics, unadjusted 
Characteristic 
Microclinic Group 
A 
(n=545) 
Individual 
Group B 
(n=187) 
Control 
Group C 
(n=188) 
Age, mean (SD), y 54.11 (10.8) 56.60 (8.81) 56.20 (9.46) 
Women, No. (%) 66.42 67.38 65.96 
Married, (%) 83.30 84.24 83.64 
Prior Diabetes Education, (%) 2.85 1.81 1.81 
Clinical Survey    
Anthropometrics, mean (SD)    
   Weight, kg 85.96 (15.23) 84.87 (16.65) 86.12 (15.08) 
   Height, m 1.60 (.09) 1.59 (.09) 1.60 (.09) 
   BMI, kg/m2 33.60 (6.36) 33.41 (6.39) 33.54 (5.31) 
   Waist, cm 104.98 (12.27) 105.85 (13.20) 105.83 (11.53) 
Blood pressure, mean (SD), mm Hg    
   Systolic 129.01 (23.51) 131.74 (22.74) 132.22 (21.67) 
   Diastolic 81.35 (12.92) 81.04 (12.80) 81.35 (11.27) 
Diabetes Factors, mean (SD)    
   HbA1c, (%) (SD) 6.89 (2.04) 6.92 (1.98) 6.90 (1.80) 
   Fasting plasma glucose, mean        
(SD), mg/dL 147.75 (63.88) 142.78 (60.34) 148.07 (57.96) 
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Primary Outcomes 
Overall, weight and BMI difference-in-differences estimates for Arm A versus control were 
statistically significant at 3-months and 6-months of the intervention. At 3-months, the DID of 
weight change in Arm A vs C was -0.574 kg (95% CI: -1.09 to -0.086; p=0.019), reflecting a 
slower weight gain in Arm A vs C; meanwhile, weight change in Arm B versus C was not 
significantly different at 3 months (p=0.198). At 6-months, the DID of weight change of Arm A 
versus C was -1.22 kg (95% CI: -1.68 to -0.478; p<0.001); in contrast, the change in weight in 
Arm B was not significantly different than in C (DID: -0.384 kg (p=0.294)). Similar to weight 
change, BMI the DID estimator was greatest for the Arm A vs C comparison at the 6-month 
point, with a DID of -0.447 kg/m2 (95%CI: -0.675 to -0.218; p<0.001). None of the DID 
estimates for BMI of Arms B vs C were significant. The net overall multi-arm test of A-B-C 
weight divergence over 6 month period was highly significant (p=0.0039). 
In CC- ITT analysis, HbA1c DID estimates were not statistically significant in A vs C and B vs C 
at 3-months and at 6-months. The overall multi-arm A-B-C test for divergence of HbA1c was 
non-significant (p=0.516). 
 
 
Inverse Probability Censoring Weight Analysis for Loss to Follow Up 
Since results based on a complete case ITT analysis are subject to selection bias from 
missingness, we also performed IPCW analyses to adjust for the loss to follow up for weight and 
HbA1c.29 Loss to follow-up appears to have been non-random, as reflected in differences in 
baseline measurements in Table S3.3: Those who missed the evaluation at 6-months or at 12-
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months were more likely to be female, were slightly younger, were slightly heavier, and had a 
slightly higher waist circumference than the average participant at baseline.  
Adjusting for missed examinations at 3-, 6-, and 12-months via IPW, the results for weight 
change in Arm A vs Arm C were similar to the results obtained via CC-ITT: the DID estimator 
for comparative weight change for Arm A vs C was statistically significant at 3-months (by -
0.646 kg, p=0.001), and even greater at 6-months (-0.911 kg, p=0.034). Via IPW analysis, the 
net overall multi-arm test of A-B-C weight divergence at 6-months was again highly significant 
(p=0.0018).  
When adjusting for loss to follow up via IPW, the change in HbA1c for Arm A vs. C was 
significant, with a DID of -0.237% (95%CI: -0.403 to -0.070; p=0.005), while B vs. C was not 
statistically different. The overall multi-arm test for HbA1c difference of A-B-C at 6 months was 
significant, p=0.020.  
Note that the overall relative effect sizes based on the IPW analyses were very similar to the 
results from the complete case analysis (Table 3.2 and 3.3). An additional sensitivity analysis, 
using the baseline value carried forward method (Table S3.5), confirmed the findings from both 
the complete case and the IPW-adjusted analysis. 
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Table 3.2. Three-month, 6-month, and 12-month Change from baseline in Clinical outcomes by Treatment Arm. Per 
Protocol Analysis. Arm C reference group. Mixed effects, multilevel model. Model adjusted for age, sex, center, cohort, 
and cycle. 
 
Change from Baseline Difference-in-Difference Estimator, p-value, 95% CI 
 3 Months 6 Months 12 Months 
 Arm A Arm B Arm A Arm B Arm A Arm B 
Weight, kg -0.574 
p=0.019* 
(-1.09, -0.086) 
-0.377 
p=0.198 
(-0.977, 0.242) 
-1.22 
p<0.001** 
(-1.68,-0.478) 
-0.384 
p=0.294 
(-1.14,0.298) 
-0.037   
p=0.908 
(-.669,0.59) 
-0.274   
p=0.481    
(1.04,0.48) 
BMI, kg/m2 -0.279   
p=0.009**  
(-.488,-0.07) 
-0.239 
 p=0.057  
(-0.485,0.007) 
-0.447   
p<0.001** 
(-.675,-.218) 
-0.081 
 p= 0.563 
 (-.356,0.194) 
-0.014   
p=0.908  
(-0.256,0.228) 
-0.0859   
p=0.564 
(-0.377, 0.206) 
Waist, cm -0.714   
p=0.268 
(-1.978,0.56) 
-1.31  
p=0.088 
(-2.82,0.194) 
-0.856   
p=0.175 
(-2.09,0.380) 
-0.762   
p=0.315 
(-2.25,0.725) 
-1.17 
p=0.078 
(-2.48,0.132) 
-1.70 
p=0.035* 
(-3.28, -0.123) 
SBP, mmHg 0.551   
p=0.770 
 (-3.15, 4.25) 
0.302      
p=0.894 
(-4.14, 4.75) 
-2.02   p=0.296 
(-5.82, 1.77) 
-0.512   
p=0.826  
(-5.08, 4.06) 
-1.61 
p=0.432 
(-5.63, 2.41) 
-3.33 
p=0.180 
(-8.19,1.54) 
HbA1c -0.091   
p=0.458 
(-0.334,0.150) 
-0.093 
p=0.528 
 (-0.38, 0.196) 
-0.237    
p=0.063 
(-0.487,0.013) 
-0.168 
p=0.271 
(-0.47, 0.131) 
-0.145   
p=0.291 
(-0.415, 0.125) 
-0.138   
p=0.405 
(-0.463, 0.187) 
FPG 
-2.03 
p=0.684 
 (-11.8, 7.73) 
0.823      
p=0.889 
(-10.8, 12.4) 
1.49   p=0.770 
(-8.54,11.5) 
-1.25   
p=0.837 
(-13.2,10.7) 
NA NA 
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Table 3.3. Analysis account for missingness via Inverse Probability Weighting: 6-month, and 12-month 
Change from Baseline in Clinical outcomes by Treatment Arm. Arm C reference group. Mixed effects, 
multilevel model, addressing LTFU/missed examinations at each endpoint via stabilized Inverse Probability 
Censoring Weights. Model adjusted for age (cat), sex (age and sex interacted), center, cohort, and cycle. 
 
Change from Baseline Difference-in-Difference Estimator, p-value, 95% CI 
 3 Months 6 Months 12 Months 
 Arm A Arm B Arm A Arm B Arm A Arm B 
Weight, kg 
-0.646   
p=0.001** 
(-1.04,-0.253) 
-0.447   p=0.185 
(-1.11,0.214) 
-0.911   
p=0.034* 
(-1.75,-.069) 
-0.220 
p=0.757 
(-1.62,1.17) 
-0.138   
p=0.801 
(-1.21,0.935) 
-0.329 
p=0.625 
(-1.65,0.991) 
BMI, kg/m2 
-0.265   
p=0.002** 
(-.435,-0.094) 
-0.184   p=0.131  
(-0.423, 0.055) 
-0.393 
p=0.005** 
(-.669,-.118) 
-0.002 
p=0.994 
(-0.568, 0.564) 
-0.008 
p=0.958 
(-0.303,.287) 
-0.085 
p=0.606 
(-0.407,0.238) 
Waist, cm 
-0.559   p=0.373 
(-1.78, 0.67) 
-1.193  
p=0.062 
(-2.44, 0.059) 
-0.433 
p=0.730 
(-2.90,2.03) 
-0.440 
p=0.710 
(-2.76,1.88) 
-1.09   
p=0.168 
(-2.64, 0.459) 
-1.54 
p=0.223 
(-4.02,0.938) 
SBP, mmHg 
-1.43    p=0.416 
(-4.87, 2.02) 
-2.82 
p=0.253 
(-7.67,2.02) 
-2.70   
p=0.120 
(-6.10,0.703) 
-0.962 
p= 0.764 
(-7.24, 5.32) 
-1.87   
p=0.270 
(-5.21,1.46) 
-3.58 
p=0.084 
(-7.63, 0.47) 
HbA1c -0.072    
p=0.417 
(-0.245,0.101) 
-0.107 
p=0.520 
(-0.433,0.219) 
-0.237   
p=0.005** 
(-.403,-.070) 
-0.206 
p=0.318 
(-0.609, 0.198) 
-0.147 
p=0.044* 
(-0.29,-0.004) 
-0.130 
p=0.494 
(-0.502,0.242) 
FPG 
-2.36   p=0.645 
(-12.4,7.69) 
-0.807    p=0.891 
(-12.3, 10.7) 
2.18   p=0.744 
 (-10.9,15.3) 
-1.85 
p=0.817 
(-17.6,13.9) 
NA NA 
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Post Intervention Follow-up: 12-months after Baseline 
However, during additional 6 months follow-up after end of intervention, results were different: 
the DID in weight change in Arm A versus Arm C was no longer significant (12-month multi-
arm A-B-C overall test p=0.882). None of the changes in weight in Arm B were significantly 
different from those in Arm C. Relative weight change never exceeded -0.4 kg in Arm B vs Arm 
C. These weight results were consistent based on CC-ITT, IPW, and BVCF analysis.  
However, for HbA1c results at 12-months post-baseline, IPW analysis found that HbA1c change 
was maintained for A vs. C with a DID of -0.147% (95% CI: -0.29 to -0.004; p=0.044), while 
HbA1c change was not maintained for B vs. C. The multi-arm A-B-C comparison of HbA1c at 12 
months was borderline significant at p=0.122. 
 
Secondary Outcomes 
The DID estimators for WC, FPG, and SBP failed to reach significance at 3-month, 6-month, 
and 12-month post baseline comparing the MC intervention to controls. These results remained 
robust to IPW (Table 3. 3) and BVCF specification. Qualitatively, we observed a relative decline 
in WC and SBP measures of A vs C, with the greatest magnitude in DID at 6-months of the 
intervention. No such trend was observed for FPG. The DID estimators for WC, FPG, and SBP 
at the reported evaluation points were not significantly different in B vs C, except for the 12-
month follow up point for WC, were the relative decline was -1.70 cm (95% CI: -3.28 to -0.123; 
p=0.035). These findings were no longer significant based on the IPW sensitivity analysis.  
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DISCUSSION 
 
 Overall, the 6-month MSN intervention program was effective in preventing weight gain and in 
somewhat improving HbA1c versus controls, while effects on secondary measures of WC, BP, 
and FPG were not supported. To our knowledge, the three-arm MSN trial represents the first 
multicenter randomized trial to test the effectiveness of leveraging social networks to improve 
obesity and diabetes in a developing country setting.   
 
Social Networks for Preventive Interventions 
Social network interactions may play a meaningful role in lifestyle modification for prevention 
and management of chronic diseases.30-33 From smoking, to alcohol use, to weight gain, the 
emerging evidence indicates that social network mechanisms are a major driver of patterns of 
lifestyle and risk factors that contribute to obesity and metabolic risks12,34,35, often to multiple 
degrees of social network separation.  Thus, if behaviors may naturally aggregate and spread in 
social networks, then interventions that leverage social networks hold potential promise to 
induce and propagate positive health behaviors by harnessing the mechanisms of social support, 
social influence, and social contagion.30,31,34,36,37 
While some lifestyle programs have involved simple social support and group-based 
interventions 38,39, few programs directly harness existing social networks to propagate and 
leverage an intervention.12,31,34,35 Moreover, existing social network-based interventions are often 
limited in scope.  For instance, the study by Vissenberg et al. recognizes the intrinsic importance 
of social networks in self-management programs to create sustainable health behavior change 
among enrolled participants. Furthermore, while there is growing literature that social network 
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mechanisms drive many lifestyle factors, much of this work has been based on passive 
observational designs.12,34,35 
 
The Microclinic Social Network Model, developed by Microclinic International, is a novel health 
program designed to leverage social network effects to improve and socially propagate positive 
health behaviors for those with, or at risk for, chronic diseases.40 More than merely providing 
social support, the Microclinic model catalyzes and leverages pre-existing clusters of friends and 
family to set healthy social norms, provide social engagement, and to create a network of 
resources with the goal of bringing about sustainable positive change.  
Our study directly addresses the question of whether health programs can harness social 
networks and if these programs are of significant clinical value.  Moreover, given the inability of 
past studies to differentiate sources of social aggregation, our longitudinal trial data helps clarify 
the role of causal induction.  
 In the light of this body of evidence, the overall results of this study reflect positively on the 
potential of leveraging social networks in propagating healthy lifestyles and in affecting large-
scale, sustained, low-cost behavior change. This will be most critical in successfully managing 
chronic disease in emerging economies. 
 
Considerations on intensity of intervention 
 While the primary outcomes in the A vs C comparison were statistically significant, the 
magnitude of the observed relative change in weight, BMI, and HbA1c were smaller than 
expected based on evidence from similar social network trials, and weight loss and diabetes 
management trials, in general. Arguably, the detected intervention effect of a 0.237% relative 
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drop in HbA1c in Arm A versus control did not reach clinical significance, which would be 
reflected in a drop of 0.6% or greater, based on other existing evidence.18 However, the long-
term effects of the intervention post 12- months are yet to be analyzed. For example, longitudinal 
studies and randomized controlled trials, with both 4-month and 10-month versions of the MSN 
demonstrated significant results at 16 and 24 months.17 We thus recommend that intervention 
intensity be augmented if the MSN intervention was to be rolled out at the national level in 
Jordan, as currently planned. A modification of the MSN program is currently in the recruitment 
phase in a new trial in Qatar. Lessons learned from this trial should be applied in this new 
setting, as contextually and culturally appropriate. Of particular importance will be to adhere to 
suggested sample size recommendations to fully power this landmark intervention, as well as to 
strongly intensify the social network interventions (to match the intensity of the previous trial in 
Kentucky), as well as to add incentives to ensure greater participant retention.   
 
Limitations 
A limitation of the herein reported results, and the trial in general, were the missed 
measurements at 6-months as well as the 12-month post-baseline follow up, at 24% and 45%, 
respectively. Study nurses reported that the large dropout at 12-months was most likely due to a 
change in phone numbers in a large number of participants (most used prepaid cellphones and 
hence changed phone numbers periodically). Additionally, instability caused by geo-political 
developments created some recruitment challenges. Tracing participants via mail also proved 
difficult, as mailing addresses were only introduced mid-way through the study, and this 
information had hence not been systematically collected at baseline. We addressed this attrition 
issue by performing several sensitivity analyses, including IPW and the BVCF method. While 
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missingness might not have been random, our main results were insensitive to our robustness 
checks. 
To reduce attrition at 16-month to 30-month follow up measurements of this trial, nurses were 
incentivized with prizes if they met the goal of 90% retention. For future trials, mid-point phone 
calls between the last treatment appointment and the first follow-up measurement appointment 
are recommended. 
Another important limitation was the modification in recruitment protocols such that the n=300 
participant requirement in both Arm B and Arm C were not met. This modification was a result 
of a petition of the nurses and on-site study personnel to provide some form of intervention to as 
many participants as possible, thereby shunting more people to be randomized to the full MSN 
Arm A program. This modification in participant size in Arm B and C reduced the power to 
detect significant intervention effects.  
As briefly mentioned above, the intensity of the social network intervention, compared to the 
education only intervention, could have been stronger. The Jordanian MSN trial represented was 
modeled on a successful MSN trial held in Kentucky, US, over a 9 to 10-month period.15,16 Due 
to staffing and resource constraints, the curriculum in Jordan was shortened and modified. This 
modification in program duration likely impacted the results, which were weaker with respect to 
clinical outcomes. Thus, an important lesson learned is that for social network effects to affect 
diabetes and obesity risk factors at clinically significant levels, high intervention intensity and 
duration to maintain network-related accountability post-treatment period are also of essence. 
 
Notwithstanding the limitations and the lessons learned, the results of the MSN trial in Jordan 
buttress existing evidence that social networks can be leveraged to propagate healthy behavior, 
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and that social network interventions might prove essential to reduce the disease and economic 
burden of non-communicable diseases in low-resource settings. Future studies that apply the 
lessons learned from this trial as well as similar studies in the US are needed to optimize 
treatment intensity, treatment length, and explore factors that can ensure sustainability of the 
intervention past the intervention period.  
 
CONCLUSION 
 
Overall, the MSN intervention was effective in significantly improving weight and BMI over a 
6-month intervention period; HbA1c results were suggestive of an improvement. The MSN 
intervention did not significantly improve waist circumference, FPG, and BP over the 6-month 
period of the trial. Further studies that leverage social networks are needed. 
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SUPPLEMENTARY APPENDIX 3 
 
MICROCLINIC SOCIAL NETWORK INTERVENTIONS FOR OBESITY AND DIABETES IN AMMAN, 
JORDAN: A 6-MONTH, 3-ARMED CLUSTER RANDOMIZED CONTROLLED TRIAL 
 
Andrea B Feigl, Daniel E Zoughbie, Kathleen T Watson, Nancy Bui, Leila Makarechi, Goodarz 
Danaei, Joshua A Salomon, David E Bloom, Till W Bärnighausen, Dana El Borno, Eric L Ding 
 
SUPPLEMENTAL TABLES  
 
Table S3.1: Timing of interventions and data collected at each intervention 
time. Abbreviations used: Wt (Weight); WC (Waist circumference); FBG (Fasting 
Blood Glucose); Ht (Height); BP (Blood Pressure: both SBP and DBP); SN (Social 
Network information);  
Week Session # Data collected 
1 1- baseline Consent form, Wt, WC, FBG, HbA1c, Ht, BP, SN, Survey 
2 2 FBG, Wt 
3 3 FBG, Wt 
4 4 Wt, WC, FBG, BP 
6 5 Wt, FBG 
8 6 Wt, WC, FBG, BP 
10 7 Wt, FBG 
12 8 Wt, WC, FBG, BP 
14 9 Wt 
16 10 Wt, WC, FBG, HbA1c, BP 
19 11* FBG, Wt 
22 12 Wt, WC, FBG, BP 
25 13 Wt 
28 14-final Wt, WC, FBG, HbA1c, BP, SN, Survey 
53 12-month Wt, WC, HbA1c, FBP, BP 
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Table S3.2: Completion rates at 6- and 12-months follow-up for weight 
Variable: Weight Arm A Arm B Arm C 
Baseline 545 187 188 
Completed month 6 403/ 545 140/ 187 122/ 188 
Completed month 12 285/ 545 109/ 187 109/188 
 
 
Table S3.3: Additional Baseline data for those who 
missed the examination (‘ME’) at 6- and 12-months 
 
 
 
  
 ME 6mo ME 12mo 
Sex (%women) 70.87 71.43 
Age (SD) 53.53 (10.8) 
53.0 
(11.6) 
Weight 87.3 (17.7) 
86.15 
(17.2) 
Height 159.7 (9.2) 
159.8 
(8.6) 
BMI 34.3 (6.4) 
33.9 
(6.7) 
Waist 
Circumference 
106.9 
(13.6) 
103.8 
(13.0) 
HbA1c 
6.86 
(1.96) 
7.20 
(2.2) 
FPG 148.6 (62.3) 
147.3 
(65.2) 
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Table S3.4: Unadjusted weight (kgs) at baseline, 3 months intervention, 6-month 
intervention, and 12-month follow-up. 
Overall weight (SD) Arm A Arm B Arm C 
Baseline 85.9 (15.1) 
85.3 
(16.0) 
85.8 
(15.0) 
3 months 83.7 (15.0) 
83.8 
(15.1) 
85.2 
(15.4) 
6 months 83.5 (15.0) 
81.7 
(15.3) 
85.8 
(14.9) 
12 months 84.6 (14.4) 
83.9 
(15.6) 
84.2 
(14.6) 
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Table S3.5: Summary statistics for Inverse Probability Censoring Weights used to adjust for loss to follow up; 
standard errors clustered at cohort level 
  3 mo 6 mo 12 mo 
 Predictors Stabilized 
IPW (SD) 
Min, Max Stabilized 
IPW (SD) 
Min, 
Max 
Stabilized 
IPW (SD) 
Min, 
Max 
Stabilized 
IPW for 
weight, 
BMI 
variables 
Sex and age (cat, 
interacted), cohort, day, 
center, treatment group, 
FPG at baseline, weight 
at baseline, weight 
change up to last visit 
before event, prior 
knowledge of diabetes 
type, highest education 
level achieved, smoking 
status, family 
encouraging of diabetes 
program, perception of 
need to change weight, 
self body image  
 
 
 
1.03   (0.171) 
.471, 2.60 1.03    (0.196) 
0.491, 
3.16 
1.04,  
(0.225)   
 
 
0.625, 
2.55 
 
Waist Ci, 
SBP, 
HBa1c,  
FPG 
As for weight and BMI, 
including FPG at 
baseline, weight at 
baseline, waist, SBP, and 
HbA1c at baseline 
1.03     
(0.184) 
 
.457, 2.62 
1.03    
(0.188)    
 
 
0.530, 
3.11 
1.04,  
(0.215)    
 
 
.563,  
2.52 
 
 
Table S3.6: Sensitivity analysis: BVCF; Variable: Weight 
Weight Change from 
Baseline (BVCF) Arm A Arm B Arm C 
3 months -0.592kg p=0.011* 
-0.447kg 
p=0.117 
(Reference) 6 months 
-0.851kg 
p=0.003** 
-0.291kg 
p=0.405 
12 months -0.122kg p=0.728 
-0.217kg 
p=0.604 
p for program*time 
interaction p<0.001 
 
 
